

Human Medicines Regulations 2012

Advisory Bodies

Commission on Human Medicines

Annual Report 2025

Published July 2026



Medicines and Healthcare products Regulatory Agency

**HUMAN MEDICINES REGULATIONS 2012
ADVISORY BODIES**

Commission on Human Medicines

**ANNUAL REPORT
2025**

**Laid before Parliament pursuant to
Part 2, Regulation 12(4) of
the Human Medicines Regulations 2012**



© Crown copyright 2026

Published by the Medicines and Healthcare products Regulatory Agency

This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3.

Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.

This publication is available at <https://www.gov.uk/mhra>

Any enquiries regarding this publication should be sent to the Medicines and Healthcare products Regulatory Agency at:

Medicines and Healthcare products Regulatory Agency

Customer Services

10 South Colonnade

Canary Wharf

London E14 4PU

Tel: 020 3080 6000

E-mail: info@mhra.gov.uk

ISBN 978-1-8384147-5-7

Printed on paper containing 40% recycled fibre content minimum

Printed in the UK by HH Associates Ltd. on behalf of the Controller of His Majesty's Stationery Office

Table of Contents

Commission on Human Medicines	7
Annual Report - 2025	8
About the Commission on Human Medicines	8
Chair's perspective on the year - Professor Sir Munir Pirmohamed	9
New active substances	9
Medicines that address unmet clinical need	9
Extension of use of approved medicines	10
The Early Access to Medicines Scheme (EAMS)	10
Orphan designations	11
Reclassification of medicines	11
Advice on Established/Generic medicines	12
Backlog Clearance	12
Regulatory and Scientific Update Session	13
Safety of Medicines	13
Policy/Strategy Advice	14
Involving patients'/carers' views at the CHM	14
Highlights of our 2025 achievements	15
Breakdown of advice provided by the Commission on Human Medicines (CHM), Expert Advisory Groups (EAG), Expert Working Groups (EWG) in 2025	17
Expert Working Groups (EWG) in 2025	18
Membership	18
Costs	18
Code of Practice for the Commission on Human Medicines and other expert advisory committees	19
Membership of the Commission on Human Medicines (CHM)	20
CHM Co-opted Members, Invited Experts and Observers	23
Membership of the Cardiovascular, Diabetes, Renal, Respiratory & Allergy Expert Advisory Group (CDRRA EAG)	26
Membership of the Chemistry, Pharmacy and Standards Expert Advisory Group (CPSEAG)	28
Membership of the Clinical Trials, Biologicals & Vaccines Expert Advisory Group (CTBVEAG)	30
Membership of the Gastroenterology, Rheumatology, Immunology & Dermatology Expert Advisory Group (GRIDEAG)	31
Membership of the Infection Expert Advisory Group (IEAG)	33
Membership of the Medicines for Women's Health Expert Advisory Group (MWHEAG)	35
Membership of the Neurology, Pain & Psychiatry Expert Advisory Group (NPPEAG)	37
Membership of the Oncology & Haematology Expert Advisory Group (OHEAG)	39

Membership of the Paediatric Medicines Expert Advisory Group (PMEAG).....	41
Membership of the Pharmacovigilance Expert Advisory Group (PEAG).....	43
Membership of the Antidepressant Risk Minimisation Expert Working Group (ARMEWG)	45
Membership of the CHM's Highly Personalised Medicines Expert Working Group (HPMEWG, formerly Cancer Vaccines EWG)	47
Membership the Real World Data Expert Working Group (RWD EWG)	51
ANNEX A - DECLARATION OF INTERESTS	52

Commission on Human Medicines

Annual Report - 2025

About the Commission on Human Medicines

The Commission on Human Medicines (CHM) is an advisory non-departmental public body, sponsored by the [Department of Health and Social Care](#) (DHSC). The CHM was established in 2005 to advise ministers and the Licensing Authority, the [Medicines and Healthcare products Regulatory Agency](#) (MHRA), on the safety, efficacy and quality of medicinal products.

The functions of the CHM are set out in [Regulation 10 of the Human Medicines Regulations \(HMR\) 2012 \(SI 2012/1916\)](#). This report presents a summary of the work undertaken by CHM in 2025.

The functions of the CHM are:

- to advise the Health Ministers and the Licensing Authority (LA) on matters relating to human medicinal products including giving advice in relation to the safety, quality and efficacy of human medicinal products where either the Commission thinks it appropriate or where it is asked to do so;
- to consider those applications where the LA has a statutory duty to refer to the CHM or chooses to do so;
- to consider representations made (either in writing or at a hearing) by an applicant or by a licence or marketing authorisation holder in certain circumstances;
- to promote the collection and investigation of information about adverse reactions to human medicines so advice can be given.

Chair's perspective on the year - Professor Sir Munir Pirmohamed

The CHM depends heavily on the dedication, knowledge, experience and time commitment of its clinical, scientific and lay experts. Their immense contribution, which is greatly appreciated and valued, ensures that the CHM bases its advice to the MHRA and the Health Ministers on rigorous examination of scientific data leading to regulatory decisions with a direct benefit to patients.

New active substances

In 2025, the CHM continued to carefully consider the data on quality, efficacy and safety of a number of new active substances. After detailed deliberations which took the inputs of appropriate expert advisory groups/invited experts into account, the CHM provided advice to the MHRA. Some examples of new medicines approved in the UK, which the CHM considered met the rigorous standards of safety, quality and effectiveness include:

- **Blujepa** (gepotidacin), a new type of antibiotic pill indicated for the treatment of uncomplicated urinary tract infections (UTIs) in females aged 12 years and older.
- **Ekterly** (sebetralstat), a medicinal product indicated for the treatment of hereditary angioedema (HAE) attacks in adults and adolescents aged 12 years and older.
- **Kostaive** (zapomeran), an mRNA vaccine to prevent COVID-19 in adults aged 18 and older.
- **Lynkuet** (elinzanetant), a non-hormonal medicinal product indicated for the treatment of moderate to severe vasomotor symptoms (hot flushes) associated with the menopause. The MHRA was the first regulator in the world to approve Lynkuet.
- **Tziield** (teplizumab), an immunotherapy to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D. It is the UK's first ever approved immunotherapy for T1D.
- **Zurzuvae** (zuranolone), a medicine for the treatment of moderate or severe postnatal depression in adults following childbirth. Zurzuvae is the first oral treatment for postnatal depression approved in the UK.

Medicines that address unmet clinical need

Some of the new medicines were in therapeutic areas where there was a great unmet medical need and, in such cases, the CHM advised the MHRA on granting either a conditional marketing authorisation (CMA) in specific circumstances where comprehensive clinical data is not yet complete, but is judged that such data will become available soon, or a marketing authorisation under exceptional circumstances, where it is not possible to provide comprehensive data on the efficacy and safety under normal conditions of use. In all such cases, these recommendations were made within the relevant statutory frameworks and were subject to clearly defined conditions, additional data requirements and ongoing regulatory oversight. This facilitated early access of new medicines to patients. Some examples where medicines were approved under a CMA include:

- **Hyrnuo** (sevabertinib), a protein kinase inhibitor that works by blocking abnormal HER2 protein for adults with HER2-positive non small cell lung cancer that has spread or cannot be removed by surgery.
- **Lagevrio** (molnupiravir), an antiviral medicine used to treat mild to moderate COVID-19 (caused by SARS-CoV-2) in adults who are at risk for developing severe illness. This was previously approved under a CMA and was updated to a marketing authorisation under exceptional circumstances as it was agreed that it would not be possible to provide comprehensive data because the prevalence of COVID-19 had significantly changed.

Extension of use of approved medicines

The CHM has also advised on the efficacy and safety of already approved medicines for use in new indications, new dose strengths or new formulations, and maintenance of authorisation of medicines approved under a CMA, based on evaluation of the emerging evidence on benefit and safety. Examples of these applications include:

- **Abrysvo** (respiratory syncytial virus subgroup a stabilised prefusion f protein 847a, respiratory syncytial virus subgroup b stabilised prefusion f protein 847b), widening of the indication to include active immunisation of individuals aged between 18 and 59 years who are at increased risk for lower respiratory tract disease caused by respiratory syncytial virus (RSV). The indication was previously restricted to individuals aged 60 years and older for the prevention of lower respiratory tract disease caused by RSV.
- **EURneffy** (adrenaline nasal spray) was approved as the first needle-free nasal spray formulation of adrenaline for the emergency treatment of anaphylaxis in the UK. Previously, adrenaline for self-administration has only been available via auto-injectors.
- **Jakavi** (ruxolitinib) widening of the indication for the treatment of patients aged 2 years and older with acute or chronic graft versus host disease (GvHD) who have inadequate response to corticosteroids. The indication was previously restricted to patients aged 12 and above. A new oral solution formulation for paediatric use was also approved.
- **Translarna** (ataluren) was approved as a renewal of a conditional marketing authorisation for the treatment of patients with Duchenne muscular dystrophy caused by a nonsense mutation (nmDMD) who are aged 2 years and older and ambulatory (able to walk).
- **Wegovy** (semaglutide), an additional higher maintenance dose of 7.2 mg once weekly (administered as 3 subcutaneous injections of 2.4 mg) was approved for the treatment of adult patients with obesity, in addition to a reduced-calorie diet and exercise. Previously, the highest approved dose was 2.4 mg.

The Early Access to Medicines Scheme (EAMS)

The Early Access to Medicines Scheme (EAMS) helps to give people with life threatening or seriously debilitating conditions early access to new medicines that do not yet have a marketing authorisation, and where there is a clear unmet medical need. The CHM gave advice to the MHRA on one EAMS application:

- **Dojolvi** (triheptanoin), a medicine indicated for the treatment of paediatric and adult patients with long-chain fatty acid oxidation disorders (LC-FAOD).

Orphan designations

The MHRA offers incentives for medicines that are granted orphan designations, which are medicines developed for the treatment of rare diseases. The incentives include market exclusivity for up to 10 years, during which another marketing authorisation will not be granted to a similar product in the approved orphan indication. Another incentive is full or partial refunds for marketing authorisation fees to encourage industry to develop medicines for rare diseases. The CHM advises the MHRA on applications for orphan designation and whether the medicine, its effects and the medical condition meet the specified criteria.

The CHM considered and discussed the eligibility of products for orphan designation and over the last year, advised on granting orphan designation for products which target rare diseases. A number of products on which the CHM has advised on orphan designation include:

- **Elahere** (mirvetuximab soravtansine), a first-in-class medicinal product indicated for the treatment of adults with ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. It is offered to patients whose cancer cells have a protein on the surface known as folate receptor-alpha (FR α), when other treatments have not worked. The CHM considered the product for fulfilment of orphan designation criteria, and the CHM advised that the condition was not rare enough to meet the criteria. Based on the CHM's advice, the applicant proceeded to a marketing authorisation approval without orphan designation.
- **Hympavzi** (marstacimab), a medicinal product indicated for routine prophylaxis of bleeding episodes in patients aged 12 years and older, with severe haemophilia A without factor VIII inhibitors, or severe haemophilia B without factor IX inhibitors. The CHM considered the product for fulfilment of orphan designation criteria and although this was a rare condition, there were other treatments available for this condition and so it does not meet the orphan designation criteria. Based on the CHM's advice, the applicant proceeded to a marketing authorisation approval without orphan designation.
- **Kinpeygo** (budesonide), a medication approved for the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion ≥ 1.0 g/day (or urine protein-to-creatinine ratio (UPCR) ≥ 0.8 g/g). This is an extension of the previously held indication. As IgAN is a rare disease that met the criteria required for orphan designation, Kinpeygo maintained its orphan designation status with the new indication.

Reclassification of medicines

Reclassification of medicines involves switching the legal status of medicines between Prescription-only medicines (POM), Pharmacy medicines (P) and General Sales List medicines (GSL). New medicines are generally approved as 'prescription-only medicines', but, over time, growing confidence in the medicine's role and improved understanding of its side effects can lead to switches to Pharmacy or General Sales List. This empowers patients' ability to self-care and alleviate the demand for NHS services.

The CHM considered the evidence and justifications supporting the applications for reclassification and advised on reclassification of medicines; examples include:

- POM to P reclassification of **Napralief** (Naproxen), for the short-term relief of muscle and joint pain (such as sprains, strains, inflammation caused by sports injuries, lower back pain, neck pain, or pain in the wrists or feet) and period pain in adults 18-50 years of age.
- POM to P reclassification of **Pirinase Allergy 0.05% Nasal Spray** (fluticasone propionate), for the prophylaxis and treatment of allergic rhinitis including hay fever and that caused by other airborne allergens such as house dust mite and animal dander in adults and adolescents 12 years and over.
- P to GSL reclassification of **Paraserts Suppositories 125 mg and 250 mg** (paracetamol), for treatment of mild to moderate pain and fever. The CHM considered the higher dose of 500 mg and concluded it to be a risk to public health. Based on the CHM's advice, the legal status of the highest dose was maintained as P.

Advice on Established/Generic medicines

The CHM also advised on the approvability of several established medicine applications. Established medicines constitute the majority of the medicines used in the UK so the MHRA needs to ensure patients and prescribers in the UK have access to safe and effective medicines of good quality. The advice from CHM in relation to such products included a wide range of topics, such as the presence of bioequivalence and therapeutic equivalence data and the acceptability of this data in different medicines; and in bibliographic applications, the demonstration of relevance of the literature to the product intended for marketing.

Backlog Clearance

The CHM played a key role in addressing the backlog of applications for clinical trial authorisation and for marketing authorisations built up at the MHRA, by providing expert advice and recommendations in the following areas:

Marketing Authorisation Applications

- The CHM, with the help of one of its Expert Advisory Groups (EAG), the Chemistry, Pharmacy and Standards (CPSEAG), reviewed more papers ranging between 25-40/month (as compared to the previous average around 10 applications) on abridged applications of generic medicinal products with known active substances over the latter part of last year, which helped in clearing the backlog in established medicines applications. This was a significant challenge to all involved to ensure that consistent levels of deep and rigorous scientific analysis of these applications were maintained while clearing the backlog.
- The main issues in these applications related to quality or joint quality/clinical, which was the expertise of the CPSEAG. The members of the CPSEAG worked in small teams over extended meeting periods to review the increased number of applications, and this provided the necessary assurance to the CHM to consider and endorse, as appropriate, the issues identified in these applications expeditiously.

Regulatory and Scientific Update Session

The CHM also held a Regulatory and Scientific Update session. The CHM heard and discussed a number of topics including:

- CHM's legal roles and responsibilities under the [Human Medicines Regulations 2012](#): regarding an overview of the legal and procedural framework governing the CHM, including its advisory role, delegation to expert groups, conflict of interest management, and the importance of transparency and collective responsibility.
- Patient Engagement and Involvement in Regulatory Processes: regarding the evolution of MHRA's patient involvement strategy, the structure and aims of patient groups, challenges in engagement, and the integration of patient voices in the pre-authorisation space and within the MHRA's rare disease work.
- Rare therapies / risk proportionate regulation: regarding the development of a new regulatory pathway for rare therapies, involving MHRA, NICE, DHSC, NHS England, patient groups, academia, and industry, with a public consultation planned for Q1 2026 and a focus on adaptive licensing, real-world evidence, and patient-centred approaches.
- AI implementation in MHRA Regulatory Processes: regarding the MHRA's AI strategy, including the ARISE program to deploy AI tools for efficiency in regulatory processes, with a focus on scientific advice drafting, clinical trial application support, and dossier data extraction.

Safety of Medicines

The CHM advised on a range of product specific issues relating to the safety of medicines over the year, including:

- Bladder antimuscarinics and the risk of dementia
- Chikungunya virus vaccine
- Cinacalcet and risk of nitrosamine impurities
- Finasteride and Dutasteride and risk of suicidal behaviour
- Givinostat and risk of sudden fatal cardiac events
- Improving the information supplied with benzodiazepines, gabapentinoids and "Z-drugs."
- Isotretinoin and the impact of the recommendations of the isotretinoin EWG
- Kaftrio and psychological side effects and the risk of drug induced liver injury
- MHRA pharmacovigilance strategy for the combined vaccine for measles mumps rubella and chickenpox
- Non- prescription codeine
- Recommendations of the Expert Working Group (EWG) on antidepressant risk minimisation for 28 antidepressants involved in the review
- Respiratory Syncytial Virus (RSV) vaccine and the risk of Guillain Barre Syndrome
- Valproate and male infertility

The CHM provided advice on risk management plans for all applications for marketing authorisation assessment for all new active substances and all known active substances. The CHM provided advice on the new safety review processes within the Benefit- Risk Evaluation function of the Safety and Surveillance Group within the MHRA to support robust

critical appraisal of the available data on safety signals and improve transparency both to the public and industry. The CHM advised on the MHRA's Women's Health Strategy.

Policy/Strategy Advice

The CHM also provided advice to the MHRA in shaping the regulatory approach for the Biosimilars National Strategy. Although not opposed to the overall principle of substituting biosimilar products, without consulting the prescriber, when safe and appropriate to do so, the CHM felt that safeguards and risk mitigating measures must be considered. The CHM considered that initial substitution of biosimilar medicines through this proposal should be with specific named biological products which are relatively safe, with a wide therapeutic index. In addition, they considered that additional detailed information on applicability and operability of the proposal was needed prior to giving their advice.

Additionally, the CHM were informed on the following subjects. The CHM welcomed these developments and expressed their views on these topics:

- ICH guidance (E21) on the inclusion of pregnant and breastfeeding individuals in clinical trials
- MHRA Guidance on Approach to MHRA's assessment of applications for medicines that use alternative methods to replace animals

Involving patients'/carers' views at the CHM

Patient views are an important component in regulatory decision making on the safety and benefit of medicines. Alongside the ongoing perspectives provided by the CHM's appointed lay members, the CHM considered written patient input submitted to the MHRA (including Yellow Card reports and direct correspondence) and welcomed opportunities to hear directly from patients, carers, families and support organisations, particularly where benefit-risk considerations were finely balanced.

Patients and families and support organisations attended meetings of the EWG on antidepressant risk minimisation. Parents, patients and support organisations' views were sought during the CHM considerations on Givinostat and Kaftrio and the information supplied with benzodiazepines, gabapentinoids and "Z-drugs."

Highlights of our 2025 achievements

In 2025, the CHM provided expert advice across hundreds of papers, supporting safe and effective medicines, patient access and ongoing public health protection.

Authorisation of safe and effective new medicines is central to advancing public health, offering new opportunities for treating certain diseases. In 2025:



The CHM reviewed and advised on:

534

papers reviewed and advised on
Across 12 scheduled monthly meetings



Type of Products:

477

Chemical product papers
Including 2
radiopharmaceutical product
papers and 19 on new active
substances

37

Biological product papers

5

**General medicinal product
papers**
Not related to any specific
medicinal product



Groups seeking CHM advice:

496

Papers from the Healthcare Quality and Access group
This included applications, risk management plan assessments and related advice.

488* Application papers Covering medicinal products, including new and known active substances, plus Risk Management Plan assessments by the S&S group.	35 Safety and Surveillance-led papers Including 11 on Pharmacovigilance Statistics and 12 on PRAC highlights**.	8 General topic papers
---	---	--

* These **488** papers concerned application for **757** medicinal products, as some papers would cover multiple medicinal products of different strengths.

Stage of advice:

390 Preliminary advice on applications	57 Final advice on applications	43 Strategy and process papers
--	---	--

36 papers were clinical trials applications, reclassifications and variations

The above papers included **1** paper under the Early Access to Medicines Scheme and **2** Conditional Marketing Authorisation renewals.

Additionally, **1** ad-hoc/extraordinary meeting was held in September, where the CHM provided advice on one clinical trial application.

Once a medicine has been authorised, the MHRA continuously monitors its quality, safety and efficacy to help keep patients safe

** Pharmacovigilance Risk Assessment Committee, each month the Commissioners are informed of the PRAC meeting highlights publication from the European Medicines Agency website

***The licensing authority seeks advice from the CHM by the form of a “paper”. A paper may cover a number of products, either pre-licensing or post-licensing, to ask for CHM’s preliminary or final advice. Preliminary Advice is CHM’s provisional opinion on the product concerned, as described in Schedule 11 of the [Human Medicines Regulations 2012 \(“HMR”\)](#). CHM’s recommendation is final following representations made by the applicant (Sch 11 of the HMR).

Breakdown of advice provided by the Commission on Human Medicines (CHM), Expert Advisory Groups (EAG), Expert Working Groups (EWG) in 2025

CHM, Expert Advisory Groups and Expert Working Groups	Abbrev.	Papers Considered and Advice Given	
		by meeting	by writing
Commission on Human Medicines	CHM	534	1
Chemistry, Pharmacy and Standards	CPSEAG	424	-
Clinical Trials, Biologicals & Vaccines	CTBVEAG	5	10
Pharmacovigilance	PEAG	38	1
Cardiovascular, Diabetes, Renal, Respiratory and Allergy	CDRRA EAG	7	-
Gastroenterology, Rheumatology, Immunology & Dermatology	GRIDEAG	3	1
Paediatric Medicines	PMEAG	20	-
Oncology and Haematology	OHEAG	8	3
Neurology, Pain & Psychiatry	NPPEAG	3	-
Medicines for Women's Health	MWHEAG	12	2
Highly Personalised Medicines Expert Working Group		17	-
Antidepressant Risk Minimisation Expert Working Group		8	-
Total Papers Considered and Advice Given		1097	

Expert Working Groups (EWG) in 2025

Summary reports based on the minutes of each meeting from the CHM's Expert Advisory Groups are published on the [GOV.UK](https://www.gov.uk) website.

Membership

Chair and Members of the Commission on Human Medicines are appointed under [Regulation 9 of the Human Medicines Regulations 2012](#), and are expected to abide by the [Code of Conduct for Board Members of Public Bodies](#) and [Governance Code for Public Appointments](#), as part of their terms and conditions of appointment. Chairs and Members of the expert advisory groups and working groups are also expected to abide by the [Code of Practice for Scientific Advisory Committees](#).

The CHM has 22 members (including the Chair) appointed by Ministers and meets 12 times a year for up to two days. In 2025, two of the 12 meetings were two-day meetings. The work of the CHM is supported by ten established Expert Advisory Groups (EAGs) as well as three Expert Working Groups (EWG) comprising of 175 experts.

EWGs are created by the CHM, in discussion with the Licensing Authority, to advise the CHM on particular specialist issues. The CHM wishes to record its gratitude and appreciation of the valuable work of its Expert Advisory Groups and Working Groups. Details of members of the CHM, its expert advisory groups and working groups are listed in this report.

Costs

The CHM Chair is entitled to claim an attendance fee of £500 for a full day, or £325 for a partial day. CHM Commissioners are entitled to claim an attendance fee of £325 for a full day or £200 for a partial day.

The Chair of an Expert Advisory Group is entitled to claim an attendance fee of £325 for a full day or £200 for a partial day. Expert Advisory Group members are entitled to claim an attendance fee of £200 for a full day or £150 for a partial day.

Travel and subsistence are also payable within standard Department of Health & Social Care guidelines.

If you are interested in learning more about CHM's work, you can find further information on the Gov.uk website: <https://www.gov.uk/government/organisations/commission-on-human-medicines>

Code of Practice for the Commission on Human Medicines and other expert advisory committees

All chairs, members, co-opted members and invited and patient experts of all our scientific advisory committees are required to declare any personal and non-personal interest, or any significant interests held by close family or friends, which may be reasonably perceived to influence their judgement in performing their functions and obligations.

Furthermore, all chairs and members must declare their interest in any items being discussed at meetings and will declare any new conflict of interest at the earliest opportunity in advance of the next meeting they attend and openly at that next meeting. These are recorded in the meetings' minutes. Where a member declares a potential conflict at meetings, the member's subsequent involvement is dealt with depending on the topic, forum and type of interest or conflict, in accordance with the Code of Practice and is recorded in the minutes.

The principles in the Code also apply to observers and invited experts who are asked to contribute written advice and do not attend committee meetings.

The Code of Practice is published on:

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1103036/2022.09.07_The_Code.pdf

The list of declared interests for chairs and members of CHM (and EAGs, EWGs and ad-hoc groups) is available below.

Membership of the Commission on Human Medicines (CHM)

Post	Name and title	Affiliations (if applicable)
Chair	Professor Sir Munir Pirmohamed ¹ MB ChB (Hons) PhD FRCP FRCP (Edin) FBPhS, FFPM (Hon) FMedSci	David Weatherall Chair of Medicine, University of Liverpool, NHS Chair of Pharmacogenetics, Director of the Wolfson Centre for Personalised Medicine, Director of the Centre for Drug Safety Science
Vice Chair	Professor Steven Cunningham ² MBChB PhD FRCPCH	Professor of Paediatric Respiratory Medicine, University of Edinburgh and Honorary Consultant, Royal Hospital for Children and Young People, NHS Lothian, Edinburgh
Member	Professor Amanda Adler ³ MD PhD FRCP	Professor of Diabetic Medicine and Health Policy, University of Oxford
Member	Professor Jamie Coleman MD MA (Med Ed) FRCP FBPhS	Consultant Physician, University Hospitals Birmingham NHS Foundation Trust and Honorary Professor in Clinical Pharmacology and Medical Education, University of Birmingham
Lay Member	Mrs Julia Cons	
Lay Member	Mr David Crundwell	
Member	Professor Paul I Dargan MB BS FRCP Edin FACMT FRCP ERT FAAct FEAPCCT FBPhS MAE FCRaz FRSB	Consultant Physician and Professor of Clinical Toxicology, Guy's and St Thomas' NHS Foundation Trust, London Professor of Clinical Toxicology, King's College London
Member	Professor David Dockrell MB BCh MD FRCPI FRCP (Glas) FACP	Professor of Infection Medicine, University of Edinburgh
Member	Professor Richard FitzGerald ⁴ MBChB PhD FRCP	Director, NIHR Liverpool Clinical Research Facility Professor of Experimental Pharmacology, University of Liverpool Honorary

¹ Reappointed 12/02/2025

² Reappointed 01/05/2025

³ Reappointed 01/05/2025

⁴ Appointed 08/09/2025

		Consultant Physician in Clinical Pharmacology and General Medicine, University Hospitals of Liverpool NHS Group
Member	Professor David Hunt MB BChir FRCP PhD	Professor of Neuroinflammatory Medicine, Wellcome Trust Senior Fellow, University of Edinburgh
Member	Professor David Moore MBChB MD MSc DTM&H	Professor of Infectious Diseases and Tropical Medicine, London School of Hygiene and Tropical Medicine and Consultant in Infectious Diseases and Tropical Medicine, Hospital for Tropical Diseases, University College London Hospital
Member	Dr Gerri Mortimore PhD; MSc Advanced Practice; PgCert (IPPE); BA(Hons) Health Studies; iLM. RGN; NMP; FHEA	Associate Professor in Advanced Clinical Practice; NICE Nurse Expert Advisor
Member	Professor Sandosh Padmanabhan ⁵ MBBS MD PhD FRCP(Glasg) FRCP(Edin) FBPhS FBIHS	Professor of Cardiovascular Genomics and Therapeutics, University of Glasgow
Member	Professor Poulam Patel PhD, MBBS, FRCP	Professor of Clinical Oncology, University of Nottingham
Member	Professor Yvonne Perrie ⁶ BSc Hons MRPharmS FAPS FSB PhD	Chair in Drug Delivery, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow. Scotland
Member	Professor Rui Providencia MD PhD	Institute of Health Informatics Research, University College London. Consultant Cardiologist & Cardiac Electrophysiologist, Barts Health NHS Trust
Member	Dr Vanessa Raymont MBChB MSc MRCPsych	Senior Clinical Researcher, University of Oxford and Honorary Consultant Psychiatrist, Oxford Health NHS Foundation Trust
Member	Professor Claire Stewart ⁷ MBBS(Hons) BMedSci(Hons) FRCGP DSRSH DRCOG MSc MedEd FAcadMed SFHEA	Dean and Head of School of Medicine, Professor of Assessment and Medical Education, The University of Nottingham, General Practitioner
Member	Professor Marc Turner MBBS PhD MBA FRCP FRCPATH FRSE	Director, Scottish National Blood Transfusion Service

⁵ End of appointment 30/04/2025

⁶ Reappointed 01/05/2025

⁷ Appointed 03/03/2025

Member	Professor Heather M Wallace PhD FRCPath FRSC FRSB FBTS FBPhS ERT	Professor Emerita of Biochemical Pharmacology and Toxicology, University of Aberdeen
Member	Professor Christopher Weir BSc (Hons) PhD MSc FRSS C.Stat	Personal Chair in Medical Statistics and Clinical Trials, Usher Institute, University of Edinburgh
Member	Professor Anthony Williams BSc MSc MRCP, FRCPath, PhD	Professor of Translational Medicine and Honorary Consultant in Clinical Immunology and Allergy, University of Southampton and University Hospital Southampton NHS Trust
Member	Dr Martin Wilson MB ChB, MPhil (Glasgow), FRCP(Edin)	Consultant Physician in Care of the Elderly, Raigmore Hospital, Inverness

CHM Co-opted Members, Invited Experts and Observers

Post	Name and title	Affiliations (if applicable)
Co-opted Member (Feb 2025)	Dr Jamie Fraser BSc (Hons) MBChB MRCP	GP Partner, Southside Surgery, Inverness
Co-opted Member (Mar, Nov)	Dr Majella Lane BSc PhD	Senior Lecturer in Pharmaceutics, UCL School of Pharmacy
Co-opted Member (May, Jul, Aug, Sep)	Professor Sandosh Padmanabhan MBBS MD PhD FRCP(Glasg) FRCP(Edin) FBPhS FBIHS	Professor of Cardiovascular Genomics and Therapeutics, University of Glasgow
Invited Expert (Feb, Sep)	Dr Tamara Griffiths	President, British Association of Dermatologists
Invited Expert (Feb, Jun, Sep)	Dr Jane Ravenscroft	Chair, Retinoids Working Party Group (British Association of Dermatologists) and Chair, Isotretinoin Implementation Advisory Expert Working Group, Commission on Human Medicines
Invited Expert (Feb)	Professor Michael Arden-Jones	Academic Vice President of the British Association of Dermatologists
Invited Expert (Feb, Jun)	Dr Chris Bower	Clinical Vice-President of the British Association of Dermatologists
Invited Expert (Mar)	Professor Gary Cook	Professor of Molecular Imaging Department of Cancer Imaging, KCL School of Biomedical Engineering & Imaging Sciences Honorary Consultant in Nuclear Medicine, Guy's & St Thomas' Hospitals NHS Foundation Trust, London
Invited Expert (Jun)	Dr Shuaib Nasser MA MBBS MD FRCP	Consultant Allergist and Respiratory Physician, Head of Allergy Cambridge University Hospital NHS Foundation Trust, Cambridge
Invited Expert (Jun)	Professor Michael Steiner MB BS BSc MD FRCP	Professor in Respiratory Medicine and Honorary Consultant, Dept of Respiratory Science, University of Leicester

Invited Expert (Aug)	Bhavana Reddy	Head of Pharmacy and Clinical Support Pharmacy and Clinical Support Team Medicines Value and Access NHS England (National)
Invited Expert (Aug)	Noor Salik	Head of Medicines Regulation and MHRA Sponsorship, Department of Health and Social Care
Invited Expert (Sep)	Dr Jamie Fraser BSc (Hons) MBChB MRCGP	GP Partner, Southside Surgery, Inverness
Invited Expert (Sep)	Professor Chris Goldring BSc PhD PGCert FBPhS	Professor of Pharmacology, Department of Pharmacology and Therapeutics, The University of Liverpool
Invited Expert (Sep)	Professor Angela E Thomas OBE MB BS PhD FRCPE FRCPPath	University of Edinburgh
Invited Expert (Oct)	Professor Gillian M Hawksworth MBE PhD FFRPS FRPharmS (Hon) DSc	Academic Community Pharmacist, Visiting Fellow at University of Huddersfield & Past President of the RPSGB
Invited Expert (Oct)	Professor Darragh Murnane PhD BSc (Pharm) PhD MRCPharm	Professor of Pharmaceutics, University of Hertfordshire
Invited Expert (Oct)	Professor Giovanni Baranello , MD, PhD	Professor of Paediatric Neuromuscular Disorders, Honorary Consultant in Paediatric Neuromuscular Diseases, UCL Great Ormond Street Institute of Child Health & Great Ormond Street Hospital
Invited Expert (Oct)	Dr John Bourke	Consultant Cardiologist, Newcastle Upon Tyne NHS Foundation
Invited Expert (Oct)	Professor Francesco Muntoni FRCPCH, FMedSc	Director, Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health & Great Ormond Street Hospital
Invited Expert (Oct)	Dr Elizabeth Wraige	Consultant paediatric neurologist, Evelina London Children's Healthcare
Invited Expert (Nov)	Professor Kevin M G Taylor BPharm PhD FRPharmS	Emeritus Professor of Clinical Pharmaceutics, UCL School of Pharmacy, London
Invited Expert (Sep, Nov)	Professor Philip (Phil) Hannaford FRSE	Emeritus Professor of Primary Care University of Aberdeen

Invited Expert (Dec)	Professor Kevin Moore BSc MB BS PhD FRCP	Professor of Hepatology, University College London
Invited Expert (Dec)	Professor Ann Daly BA PhD FBPhS	Professor of Pharmacogenetics, Faculty of Medical Sciences, Newcastle University
Invited Expert (Dec)	Mr Robin Hamilton FRCOphth	Consultant Ophthalmic Surgeon, Moorfields Eye Hospital, Honorary Senior Lecturer, Institute of Ophthalmology, UCL
Observers	Officials from National Institute for Health and Care Excellence (NICE) have observed the following meetings: Mar, Apr, Aug, Oct, Dec	
Observers	Officials from United Kingdom Health Security Agency (UKHSA) have observed the following meetings: • May, Jul, Sep, Oct	
Observers	Officials from Devolved Nations Administrations (Wales) have observed the following meetings: • May, Sep, Oct	
Observers	British Association of Dermatologists • Sep	

Membership of the Cardiovascular, Diabetes, Renal, Respiratory & Allergy Expert Advisory Group (CDRRA EAG)

Post	Name and title	Affiliations (if applicable)
Chair	Professor Amanda Adler ⁸ MD PhD FRCP (London)	Professor of Diabetic Medicine and Health Policy, University of Oxford
Member	Dr Amine Boualem MD MRCGP PGDip(Diabetes) AHEA	GP Partner, East Barnwell Health Centre, Cambridge
Member	Professor Mark Evans Bsc MB BS MD FRCP	University Professor of Diabetic Medicine & Honorary Consultant Physician Institute of Metabolic Science & Department of Medicine University of Cambridge
Member	Professor William G. Herrington MA(Cantab) MBBS(London) MD(Cantab) FRCP(London) FERA	Professor of Trials and Epidemiology of Kidney Disease, Nuffield Department of Population Health (NDPH), University of Oxford; Honorary Consultant Nephrologist, Oxford Kidney Unit
Member	Dr Patrick Holmes MB BS MSc MRCGP	GP Partner St. George's Medical Practice, Darlington
Member	Dr Wajid Hussain BSc (Hons) MB ChB (Hons) MSc FRCP	Consultant Cardiologist, Royal Brompton and Harefield Hospitals, Part of Guys and St Thomas' NHS Foundation Trust
Member	Dr Hassan Kahal PhD, FRCP	Consultant in Diabetes, Endocrinology, and Obesity Medicine, Clinical Lead for Tier-3 Obesity Service, North Bristol NHS Trust, Bristol
Member	Professor Theresa McDonagh ⁹ BSc (Hons), MB ChB (Hons), MD (Distinction), FRCP, FESC, FHFA	Consultant Cardiologist, King's College Hospital, London & Professor of Heart Failure King's College, London
Member	Dr Shuaib Nasser MA MBBS MD FRCP	Consultant Allergist and Respiratory Physician, Head of Allergy Cambridge University Hospital NHS Foundation Trust, Cambridge

⁸ Reappointed 01/05/2025

⁹ Reappointed 20/01/2025

Lay Member	Ms Asha Odedra ¹⁰ MBE, BA (Hons)	
Member	Professor Sandosh Padmanabhan ¹¹ MBBS MD PhD FRCP(Glasg) FRCP(Edin) FBPhS FBIHS	Professor of Cardiovascular Genomics and Therapeutics, University of Glasgow
Member	Professor John Petrie BSc(Hons) MBChB PhD FRCP(Glasg) FRCP(Edin)	Professor of Diabetes & Director of Glasgow Clinical Trials Unit, University of Glasgow
Member	Professor Anita K Simonds MD FRCP FERS	Professor Emeritus of Respiratory and Sleep Medicine, National Heart and Lung Institute, Imperial College, London & Honorary Consultant Respiratory and Sleep Physician, Royal Brompton & Harefield Hospital, Sydney Street, London, Harveian Librarian, Royal College of Physicians, London
Member	Dr Rona Smith MA(Cantab) MB BChir(Cambridge) MD(Cantab) MRCP(London)	Associate Professor of Nephrology, University of Cambridge; Honorary Consultant in Nephrology and Vasculitis, Cambridge University NHS Foundation Trust.
Member	Professor Michael Steiner ¹² MB BS BSc MD FRCP	Professor in Respiratory Medicine and Honorary Consultant, Dept of Respiratory Science, University of Leicester
Lay Member	Mr Nigel Westwood ¹³	

¹⁰ Appointed 03/03/2025

¹¹ Reappointed 01/05/2025

¹² End of appointment 04/07/2025

¹³ Appointed 03/03/2025

Membership of the Chemistry, Pharmacy and Standards Expert Advisory Group (CPSEAG)

Post	Name and title	Affiliations (if applicable)
Chair	Professor Yvonne Perrie ¹⁴ BSc Hons MRPharmS FAPS FSB PhD	Chair in Drug Delivery, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow. Scotland
Vice Chair	Dr Majella Lane ¹⁵ BSc PhD	Professor of Pharmaceutics and Director of the UCL Drug Delivery Group
Member	Professor Hannah Batchelor ¹⁶ BSc PhD	Professor of Pharmaceutics and Biopharmaceutics, Strathclyde Institute of Pharmaceutical and Biomedical Sciences, University of Strathclyde
Member	Dr Federico Brucoli Pharm. D., PhD, CChem MRSC, mGPhC, FHEA	Associate Professor in Medicinal Chemistry, Leicester School of Pharmacy, De Montfort University, Leicester
Member	Professor Barbara R Conway ¹⁷ BSc (Pharm) PhD FRPharmS CMgr FCMI	Head of Pharmacy and Professor of Pharmaceutics, University of Huddersfield, Huddersfield
Member	Professor Ben Forbes BPharm PhD	Professor of Pharmaceutics, Institute of Pharmaceutical Science, Kings College London
Member	Professor Nikoletta Fotaki MSc, PhD, FAAPS	Professor of Biopharmaceutics, Department of Life Sciences, University of Bath
Member	Professor Vitaliy Khutoryanskiy ¹⁸ BSc, MSc, PhD, FRSC, FAPS	Professor of Formulation Science, University of Reading
Member	Mr Robert Lowe BPharm FRPharmS	Former hospital pharmacist and Quality Assurance Specialist Lead Pharmacist for Specialist Pharmacy Services (NHS England)

¹⁴ Reappointed 01/05/2025

¹⁵ Reappointed 11/12/2025

¹⁶ Reappointed 30/08/2025

¹⁷ Reappointed 30/08/2025

¹⁸ Appointed 03/02/2025

Member	Professor Luigi (Gino) Martini BSc (Hons), PhD, MBA, FRPharmS, FRSC	Chief Executive Precision Health Technology Accelerator (PHTA), University of Birmingham Honorary Professor in Pharmacy, University of Birmingham
Member	Professor Afzal R Mohammed ¹⁹ BPharm PhD	Professor of Pharmaceutics, Aston Pharmacy School, Aston University
Member	Professor Darragh Murnane PhD BSc (Pharm) PhD MRCPPharm	Professor of Pharmaceutics, University of Hertfordshire
Lay Member	Mrs Ruth Paulin BPharm MRPharmS	
Member	Professor Kevin M G Taylor ²⁰ BPharm PhD FRPharmS	Emeritus Professor of Clinical Pharmaceutics, UCL School of Pharmacy, London
Member	Professor Susannah E Walsh PhD BSc MBA	Head of School, Professor of Pharmaceutical Microbiology, Pharmacy and Life Sciences, Robert Gordon University
Member	Mr Hadar Zaman ²¹ MPharm, MFRPSII, IPresc, FHEA	Chief Pharmacist, North Cumbria Integrated Care NHS Foundation Trust

¹⁹ Reappointed 30/08/2025

²⁰ Appointed 03/02/2025

²¹ Reappointed 01/11/2025

Membership of the Clinical Trials, Biologicals & Vaccines Expert Advisory Group (CTBVEAG)

Post	Name and title	Affiliations (if applicable)
Chair	Professor Marc Turner MB ChB PhD MBA FRCP FRCPATH FRSE	Director, Scottish National Blood Transfusion Service
Member	Professor Farzin Farzaneh DPhil FRCPATH FRSB	Professor of Molecular Medicine, King's College London. Honorary Consultant in Specialist Medicine, King's College Hospital NHS Trust
Member	Professor Chris Goldring ²² BSc PhD PG Cert FBPhS	Professor of Pharmacology, Department of Pharmacology and Therapeutics, The University of Liverpool.
Member	Professor Teresa Lambe ²³ OBE BSc(Hons) PhD FRSB FMedSci	Calleva Head of Vaccine Immunology, Oxford Vaccine Group, Pandemic Sciences Institute, University of Oxford
Lay Member	Dr Kirstie Shearman LLB MA PhD	Policy Manager, Health Research Authority
Member	Dr Robin Thorpe ²⁴ PhD FRCPATH	Retired, Head, Division of Biotherapeutics, National Institute for Biological Standards and Control (NIBSC)
Member	Professor Merryn Voysey ²⁵ DPhil	Professor of Statistics in Vaccinology, Oxford Vaccine Group, Department of Paediatrics, University of Oxford
Member	Professor Christina Yap ²⁶ MSc PhD Cstat	Professor of Clinical Trials Biostatistics, Team Leader in Early Phase and Adaptive Trials Team, ICR-Clinical Trials and Statistics Unit, The Institute of Cancer Research

²² Reappointed 06/08/2025

²³ Appointed 06/01/2025

²⁴ Reappointed 13/04/2025

²⁵ Appointed 02/06/2025

²⁶ End of Appointed 05/08/2025

Membership of the Gastroenterology, Rheumatology, Immunology & Dermatology Expert Advisory Group (GRIDEAG)

Post	Name and title	Affiliations
Chair	Professor Anthony Williams BSc MSc MRCP FRCPATH PhD	Professor of Translational Medicine and Honorary Consultant in Clinical Immunology and Allergy, University of Southampton and University Hospital Southampton NHS Trust
Member	Professor Michael Arden-Jones ²⁷ BSc MBBS DPhil FRCP	Associate Professor, University of Southampton and Consultant Dermatologist
Member	Professor Anjan Dhar ²⁸ DM, MD (Medicine), FRCPE, AGAF, Cert. Med. Ed, FHEA	Professor of Medicine (Teesside University), Consultant Gastroenterologist, Clinical Lead for UGI Cancers, County Durham & Darlington NHS Foundation Trust
Member	Dr Shahida Din BMSc, MBChB, PhD, FRCP (Edin)	Consultant Gastroenterologist & NHS Research Scotland Clinician, NHS Lothian; Honorary Senior Clinical Lecturer, University of Edinburgh
Member	Professor Celia Moss OBE BA(Hons) MB BS MA MRCP DM FRCP MRCPC	Honorary Consultant Dermatologist, Birmingham Women's and Children's NHS FT; Honorary Professor of Paediatric Dermatology, University of Birmingham
Lay Member	Mr James Pitayanukul ²⁹ BSc (Hons) MSc CA	
Member	Professor Stuart H Ralston ³⁰ MB ChB MD FRCP FMedSci FRSE FFPM (Hon)	Professor of Rheumatology, Western General Hospital, University of Edinburgh
Member	Dr Ravishankar Sargur ³¹ MD, FRCPATH, FRCP, MBA	Consultant Clinical Immunologist and Clinical Lead for Laboratory Immunology, Northern General Hospital, Sheffield

²⁷ End of appointment 16/09/2025

²⁸ Reappointed 01/07/2025

²⁹ Reappointed 22/03/2025

³⁰ Reappointed 18/02/2025

³¹ Reappointed 18/02/2025

Member	Professor Nidhi Sofat ³² PhD MBBS FRCP PGCert FHEA	Professor of Rheumatology, City St Georges University London and St George's University Hospitals NHS Foundation Trust
---------------	---	---

³² Reappointed 22/01/2025

Membership of the Infection Expert Advisory Group (IEAG)

Post	Name and title	Affiliations (if applicable)
Chair	Professor David Dockrell MB BCh MD FRCPi FRCP (Glas) FACP	Professor of Infection Medicine, University of Edinburgh
Member	Professor Brian Angus BSc, MBChB, MA (Oxon), MD (Glas) DTM&H, FRCP, FFTM (Glas)	Reader in Infectious Diseases and Professor of Practice, Medical Education, Chair of the UK Malaria Expert Advisory Group (UKMEAG)
Member	Dr Michael Brown ³³ BA BM BCh FRCP PhD DTM&H	Consultant Physician, Infectious Diseases & Acute Medicine, & Clinical Director, Division of Infection, University College London Hospitals NHS Foundation Trust & Honorary Associate Professor, Clinical Research Sept, London School of Hygiene & Tropical Medicine
Member	Professor Geraint Rhys Davies ³⁴ BM DTM&H PhD FRCP	Professor of Infection Pharmacology, University of Liverpool, Honorary Consultant in Infectious Diseases, Liverpool University Hospitals Foundation Trust
Member	Professor Andrew Freedman ³⁵ M.A, M.B, B. Chir, M.D, FRCP (Lond.), FRCP (Edin.)	Consultant in Infectious Diseases / Vaccine Trials, Cardiff & Vale UHB, Honorary Professor, Cardiff University School of Medicine
Member	Professor Louis Grandjean ³⁶ MBBS BSc MSc PhD MRCPCH	Associate Professor Paediatric Infectious Diseases Great Ormond Street Hospital and University College London
Member	Dr Lim S Jones ³⁷ MBBCh, PhD, FRCPPath.	Consultant Microbiologist, Public Health Wales Microbiology, Cardiff; Clinical Lead Specialist Antimicrobial Chemotherapy Unit, Cardiff; Chair of the All Wales Medical Microbiology Development & Standardisation Group

³³ Reappointed 01/11/2025

³⁴ Reappointed 01/08/2025

³⁵ End of appointment 10/12/2025

³⁶ Reappointed 01/08/2025

³⁷ Reappointed 01/11/2025

Lay Member	Mrs Stella O'Brien³⁸ MA (Hons) PhD (hc)	
Member	Dr Matthias Schmid MD FRCP DTMH	Consultant Physician, Head of Department of Infection & Tropical Medicine, Directive of Elective Studies Newcastle University, Royal Victoria Infirmary, Newcastle upon Tyne
Member	Professor Richard J C Gilson³⁹ MD FRCP	Professor of Sexual Health & HIV Medicine, Director of the UCL Centre for Clinical Research in Infection & Sexual Health

³⁸ Reappointed 30/06/2025

³⁹ End of appointment 16/09/2025

Membership of the Medicines for Women's Health Expert Advisory Group (MWHEAG)

Post	Name and title	Affiliations
Chair	Professor Philip Hannaford MBChB MD FRCGP FFPH FFSRH FRSE	Emeritus Professor of Primary Care, University of Aberdeen
Vice Chair	Dr Diana Wellesley FRCP	Honorary Consultant and Honorary Senior Lecturer in Clinical Genetics, Wessex Clinical Genetics Service, Princess Anne Hospital Southampton
Lay Member	Dr Caitlin Dean RGN MSc PhD	Chair Trustee, Pregnancy Sickness Support
Member	Dr Kenneth Hodson MD MBChB MRCP(UK) MRCOG	Head of UK Teratology Information Service, UK Teratology Information Service
Member	Dr Sylvia Kama-Kieghe FRCGP FRSM FRSPH DFSRH	Consultant in General Practice and Urgent Care, Sheffield GP Out of Hours. GP Tutor and Examiner, University of Sheffield. Digital Health Educator and Clinical Lead, Alevyn Ltd.
Member	Dr Asha Kasliwal ⁴⁰ FRCOG FFRSH FRCGP (Hon) FFPH (Hon)	Consultant in Community Gynaecology and Reproductive Health, Manchester University NHS Foundation Trust Hathersage Centre
Member	Dr Jonathan Lord MD FRCOG FHEA	Consultant Obstetrician and Gynaecologist, Royal Cornwall Hospitals NHS Trust
Member	Professor Laura A. Magee MD (Hons) MSc FRCPC CertClinPharm FACP FRCOG	Professor of Women's Health, King's College London
Member	Dr Louise Massey ⁴¹ MBChB FFSRH FFPH	Consultant in Sexual and Reproductive Health Aneurin Bevan University Health Board
Member	Dr Laura Oakley ⁴² BSc MSc PhD	Associate Professor, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine

⁴⁰ Reappointed 27/01/2025

⁴¹ Reappointed 27/01/2025

⁴² Reappointed 30/06/2025

Lay Member	Ms Linda Pepper ⁴³ BA MA (Education)	Independent Consultant: patient and public involvement in healthcare
Member	Dr Julia Prague ⁴⁴ MBBS PhD MRCP(UK) BSc	Consultant in Endocrinology, Diabetes, and General Internal Medicine, Royal Devon and Exeter NHS Foundation Trust, and Honorary Senior Clinical Lecturer, College of Medicine and Health, University of Exeter
Member	Professor Stuart H Ralston MB ChB MD FRCP FMedSci FRSE FFPM (Hon)	Professor of Rheumatology, University of Edinburgh, Western General Hospital, Edinburgh
Member	Professor Laurie Tomlinson ⁴⁵ MBBS MSc PhD	NIHR research Professor, Faculty of Epidemiology and Population Health London School of Hygiene & Tropical Medicine

⁴³ End of appointment 16/07/2025

⁴⁴ End of appointment 14/02/2025

⁴⁵ End of appointment 06/01/2025

Membership of the Neurology, Pain & Psychiatry Expert Advisory Group (NPPEAG)

Post	Name and title	Affiliations
Chair	Professor David Hunt MB BChir FRCP PhD	Consultant Neurologist, NHS Lothian; Professor of Neuroinflammatory Medicine, University of Edinburgh
Member	Dr Lisa Brownell BSc(Hons) MBChB PGCertMedEd FHEA FRCPsych	Associate Medical Director, Birmingham and Solihull Mental Health NHS Foundation Trust; Chair of Area Prescribing Committee, Birmingham, Sandwell, Solihull and Environs
Member	Dr Barry Mark Miller ⁴⁶ MB ChB FRCA FFPMRCA	Consultant in Pain Medicine and Anaesthesia, Bolton NHS Foundation Trust; Board Member of the Faculty of Pain Medicine
Member	Professor Richard Nicholas ⁴⁷ BSc, MB BS, MSc, FRCP (Lond), PhD, BA, MBA,	Consultant Neurologist and Professor of Practice Imperial Healthcare NHS Trust and Imperial College. Vice Chair HTA committee National Institute for Health and Care Excellence
Lay Member	Mrs Stella O'Brien ⁴⁸ MA (Hons) PhD (hc)	
Member	Professor David G C Owens ⁴⁹ MD (Hons) FRCP FRCPsych	Professor Emeritus of Clinical Psychiatry, Edinburgh University
Member	Dr Waqar Rashid ⁵⁰ MBBS BSc MRCP(UK) PhD	Consultant and Honorary Clinical Senior Lecturer in Neurology, Brighton and Sussex University Hospitals NHS Trust, member of the Multiple Sclerosis Society
Member	Dr Fergus Rugg-Gunn MB BS MRCP PhD	Consultant Neurologist, National Hospital for Neurology and Neurosurgery, Queen Square, London

⁴⁶ Reappointed 01/09/2025

⁴⁷ Appointed 08/09/2025

⁴⁸ Appointed 08/09/2025

⁴⁹ End of appointment 10/03/2025

⁵⁰ End of appointment 11/12/2025

Member	Dr Aditya Sharma ⁵¹ MBBS MD MRCPsych PhD	Clinical Senior Lecturer and Hon Consultant in child and adolescent psychiatry, Newcastle University and Clinical Lead for National Specialist Adolescent Mood disorders Service, CNTW NHS Foundation Trust
Member	Professor James Stone ⁵² BSc(Hons) MBBS PhD FRCPsych	Professor of Psychiatry, Brighton and Sussex Medical School (BSMS), University of Sussex. Honorary Consultant in Liaison Psychiatry, Sussex Partnership NHS Foundation Trust.
Member	Dr Hoo Kee Tsang ⁵³ BSc(Hons) MB BCh FRCA FFPMRCA, MBA(Hons)	Consultant in Pain Medicine and Anaesthesia, Clinical Director of Pain Services, Liverpool University Hospitals NHS Foundation Trust, member of the Royal College of Anaesthetists and the Faculty of Pain Medicine training and assessment committees

⁵¹ Reappointed 14/07/2025

⁵² Appointed 08/09/2025

⁵³ Reappointed 09/12/2025

Membership of the Oncology & Haematology Expert Advisory Group (OHEAG)

Post	Name and title	Affiliations
Chair	Professor Poulam Patel PhD, MBBS, FRCP	Professor of Clinical Oncology, University of Nottingham
Vice Chair	Professor James Spicer ⁵⁴ FRCP, PhD	Professor of Experimental Cancer Medicine, King's College London; Consultant in Medical Oncology, Guy's & St Thomas' NHS Foundation trust
Member	Professor Janet E Brown ⁵⁵ FRCP, MD, MSc, BMedSci, MBBS	Academic Unit of Clinical Oncology, Department of Oncology and Metabolism, Weston Park Hospital, University of Sheffield
Member	Dr Perminder Tony Singh Dhillon Bsc, MB BS, FRCP, PhD	Consultant Medical Oncologist, Royal Surrey Hospital, Guildford, Surrey and Hon. Senior Lecturer in Oncology, University of Surrey
Member	Professor Martin Kaiser ⁵⁶ MD, FRCP, FRCPATH	Professor of Haematology, The Institute of Cancer Research, London; Honorary Consultant Haemato-oncologist, The Royal Marsden Hospital, London
Member	Dr Anjum Khan PhD MBChB FRCPATH MRCP	Consultant Haematologist, Leeds Teaching Hospitals NHS Trust
Member	Dr Rebecca Kristeleit ⁵⁷ BSc MBChB PhD FRCP FRSB	Consultant Medical Oncologist, Guy's and St Thomas' NHS Foundation Trust
Member	Professor Siow-Ming Lee ⁵⁸ PhD FRCP	Professor of Medical Oncology, Consultant Medical Oncologist
Member	Dr Debashis Sarker MBChB PhD FRCP	Reader in Experimental Oncology, King's College London Consultant Medical Oncologist, Guy's, St Thomas' and King's College Hospitals

⁵⁴ Reappointed 11/03/2025

⁵⁵ Reappointed 18/02/2025

⁵⁶ Appointed 03/02/2025

⁵⁷ Reappointed 18/02/2025

⁵⁸ Reappointed 11/03/2025

Member	Dr Ben Uttenthal MA MB BS PhD MRCP FRCPath	Consultant Haematologist, Cambridge University Hospitals
---------------	---	--

Membership of the Paediatric Medicines Expert Advisory Group (PMEAG)

Post	Name and title	Affiliations
Chair	Professor Steven Cunningham ⁵⁹ MBChB PhD FRCPCH	Professor of Paediatric Respiratory Medicine, University of Edinburgh and Honorary Consultant, Royal Hospital for Children and Young People, NHS Lothian, Edinburgh
Vice Chair	Dr Kathryn Johnson ⁶⁰ MBChB FRCPCH	Consultant Neonatologist & Research Lead. Leeds Teaching Hospitals NHST, Clinical Lead, National Disease Registration Service (NDRS), NHS England.
Member	Mrs Catrin Barker FRPharmS	Pharmacist
Member	Dr Simon B Drysdale BSc (Hons) MBBS PgDipPID PhD FRCPCH FHEA	Associate Professor, University of Oxford; Honorary Consultant in Paediatric Infectious Diseases and Immunology, Oxford University Hospitals NHS Foundation Trust
Member	Dr Martin William English ⁶¹ BMSc, MBChB, MD, FRCP(Glas), FRCPCH	Honorary Consultant Paediatric Oncologist, Birmingham Women's and Children's Hospital NHS Foundation Trust
Member	Professor Daniel Hawcutt BSc (Hons), MB ChB (Hons), MD, MRCPCH	Professor Paediatric Clinical Pharmacology, Department of Women's and Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, Honorary Consultant Alder Hey Children's Hospital, Director of Liverpool Institute of Child Health and Wellbeing
Member	Dr Caroline Jones ⁶² MB ChB FRCPCH MD	Consultant Paediatric Nephrologist, Alder Hey Children's Hospital NHS Foundation Trust
Member	Dr Ashley Liew MBChB, MRCPsych, MSc	Consultant Paediatric Neuropsychiatrist, Evelina London Children's Hospital, and South London & Maudsley NHS Foundation Trust. Honorary Associate Professor, University of Warwick.

⁵⁹ Reappointed 01/05/2025

⁶⁰ Reappointed 18/02/2025

⁶¹ Reappointed 27/01/2025

⁶² Reappointed 17/02/2025

Member	Dr Daniel E Lumsden ⁶³ MB/BChir MA Cantab MSc PhD FRCPCH	Consultant Paediatric Neurologist, Evelina London Children's Hospital Adjunct Clinical Senior Lecturer, Department of Perinatal Imaging, King's College London
Lay Member	Dr Jacqueline McMurtrie BSc (Hons), MSc, PhD	
	Dr Oliver Morris ⁶⁴ BA PhD MBBS DCH FRCGP	Salaried GP, Shirley Health Partnership, Southampton
Member	Dr Clare Pain ⁶⁵ BMBS, MSc, MRPCH	Consultant Paediatric Rheumatologist, Clinical Lead for Rheumatology Honorary Clinical Lecturer, University of Liverpool Associate Director, UK Experimental Arthritis Treatment Centre for Children (Behcet's and scleroderma workstreams)
Member	Professor Guido Piele s PhD MD	Honorary Consultant cardiologist at Bristol Congenital Heart Centre Associate Professor at UCL in Sports Cardiology
Member	Professor Shirley Price MSc PhD FBTS FRSB ERT FHEA FRSC MBPharmacolSoc	Emerita Professor of Toxicology, University of Surrey Visiting Professor of Toxicology, University of Hertfordshire Honorary Professor of Toxicology, UKHSA
Member	Mrs Julia Taylor ⁶⁶ MSc BSc	Paediatric Advanced Nurse Practitioner, High Dependency Unit, Alder Hey Children's NHS Foundation Trust.
Lay Member	Mrs Rhian Thomas-Turner LLM, PG Dip Legal Practice	Research and Development Lead, Noah's Ark Children's Hospital for Wales, Cardiff and Vale University Health Board
Member	Dr David Tuthill ⁶⁷ MB BCh FRPCH	Consultant Paediatrician Children's Hospital for Wales, Cardiff Review Editor Medicines for Children, RCPCH London Paediatric Formulary Committee Chairman, BNFc, Royal Pharmaceutical Society
Member	Dr William John Watkins ⁶⁸ BSc PhD	Senior Statistician/Lecturer, College of Biomedical & Life Sciences, Cardiff University

⁶³ Reappointed 27/01/2025

⁶⁴ Appointed 03/02/2025

⁶⁵ Reappointed 18/02/2025

⁶⁶ End of Appointment 16/05/2025

⁶⁷ Appointed 03/03/2025

⁶⁸ Reappointed 18/02/2025

Membership of the Pharmacovigilance Expert Advisory Group (PEAG)

Post	Name and title	Affiliations (if applicable)
Chair	Professor Jamie Coleman MD MA (Med Ed) FRCP FBPhS	Consultant Physician, University Hospitals Birmingham NHS Foundation Trust and Honorary Professor in Clinical Pharmacology and Medical Education, University of Birmingham
Vice Chair	Professor Daniel Hawcutt ⁶⁹ BSc (Hons) MB ChB (Hons) MD, MRCPCH	Professor Paediatric Clinical Pharmacology, Department of Women's and Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, Honorary Consultant Alder Hey Children's Hospital, Director of Liverpool Institute of Child Health and Wellbeing
Member	Mrs Alana Adams BPharm (Hons) MSc IP MRPharmS	Principal Pharmacist Medicines Information, advice and Safety, University of Cardiff
Member	Professor Darren Ashcroft ⁷⁰ BPharm MSc PhD FRPharmS	Professor of Pharmacoeconomics, University of Manchester
Member	Professor Ann Daly ⁷¹ BA PhD HonFBPhS	Professor Emerita of Pharmacogenetics, Faculty of Medical Sciences, Newcastle University
Member	Dr Tom Fairfax ⁷² BMBCh, MA, MSt MedEd, DPhil, DCH, DOccMed, FHEA, MRCP, MRCP, MRCP	Senior Clinical Lecturer, School of Medicine, University of Sunderland
Member	Professor Richard FitzGerald MBChB PhD FRCP	Director, NIHR Liverpool Clinical Research Facility Professor of Experimental Pharmacology, University of Liverpool Honorary Consultant Physician in Clinical Pharmacology and General Medicine, University Hospitals of Liverpool NHS Group
Lay Member	Ms Susan Hunneyball ⁷³ BSc (Hons)	

⁶⁹ Reappointed 11/12/2025

⁷⁰ Reappointed 11/12/2025

⁷¹ Reappointed 11/12/2025

⁷² Appointed 01/07/2025

⁷³ Reappointed 11/12/2025

Member	Professor Patricia McGettigan BSc (Pharm) MD FRCPI FRACP SFHEA FBPhS	Professor of Clinical Pharmacology and Medical Education, Queen Mary University of London; Consultant Physician, Barts Health NHS Trust
Member	Dr Fraz A. Mir ⁷⁴ MA FRCP	Consultant Physician, Cambridge University Hospitals NHS Foundation Trust
Lay Member	Dr Malcolm Oswald	Honorary Research Fellow in Law, University of Manchester
Member	Professor Rupert Payne ⁷⁵ MB ChB PhD MRCGP FRCPE FBPhS FHEA	Professor of Primary Care & Clinical Pharmacology University of Exeter
Member	Dr Nashat Qamar MB ChB MRCGP MSc DRCOG BSc (hons)	PCN Clinical Director and GP Partner, Hall Green Health, Birmingham.
Member	Dr Anna Schultze BSc MSc PhD	Assistant Professor in Pharmacoepidemiology, Faculty of Epidemiology and Public Health, London School of Hygiene and Tropical Medicine
Member	Dr Rajeev Shah ⁷⁶ MA MB BChir MRCGP DCH DFFP DC&CBT MBA	Clinical Director, East London Foundation Trust
Member	Professor Reecha Sofat MBBS, FRCP, PhD	Breckenridge Chair of Clinical Pharmacology and Therapeutics, University of Liverpool

⁷⁴ Reappointed 24/11/2025

⁷⁵ End of Appointment 13/07/2025

⁷⁶ Appointed 01/07/2025

Membership of the Antidepressant Risk Minimisation Expert Working Group (ARMEWG)

Post	Name and title	Affiliations
Chair	Professor Angela Thomas OBE MB BS PhD FRCPE FRCPath	University of Edinburgh
Lay Member	Ms Susan Hunneyball BSc (Hons)	Member of the Pharmacovigilance Expert Advisory Group (PEAG) and Advisory Board on the Registration of Homeopathic Products (ABRHP)
Lay Member	Ms Linda Pepper BA MA (Education)	Member of the Medicines for Women's Health Expert Advisory Group (MWHEAG) and the Isotretinoin Expert Working Group (IEWG)
Member	Professor Tony Avery OBE	GP and Professor of Primary Health Care, National Clinical Director for Prescribing (NHS England)
Member	Professor Arianna Di Florio MD PhD	Professor of Psychiatry, Cardiff University
Member	Professor Nicol Ferrier	Professor of Psychiatry, Institute of Neuroscience, Newcastle University
Member	Dr Jamie Fraser BSc (Hons) MBChB MRCP	GP Partner, Southside Surgery, Inverness
Member	Ellie Gordon	Royal College of Nursing
Member	Professor David Kessler MD MRCP MRCPsych MBBS BA	Professor of Primary Care, Bristol Medical School, University of Bristol
Member	Professor Glyn Lewis	Professor of Psychiatric Epidemiology, University College London
Member	Dr Barry Miller MB Ch.B FRCA FFPMRCA FCEM	Consultant, Pain Management and Anaesthetics, Bolton NHS Foundation Trust
Member	Professor David G C Owens MD (Hons) FRCP FRCPsych	Professor Emeritus of Clinical Psychiatry, the University of Edinburgh
Member	Mr Peter Pratt	National Specialty Adviser for mental health pharmacy, NHS England
Member	Professor Vanessa Raymont MBChB MSc MRCPsych	Associate Professor, University of Oxford and Honorary Consultant Psychiatrist, Oxford Health NHS Foundation Trust

Member	Dr Aditya Sharma	Consultant Child & Adolescent Psychiatrist/Clinical Lead, Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust
Member	Professor David Taylor FRPharmS FRCPE FRCPsych (Hon)	Director of Pharmacy and Pathology, King's College London
Member	Dr Hoo Kee Tsang BSc(Hons) MB BCh FRCA FFPMRCA	Consultant in Pain Medicine and Anaesthesia, Clinical Director of Pain Services, Liverpool University Hospitals NHS Foundation Trust, member of the Royal College of Anaesthetists and the Faculty of Pain Medicine training and assessment committees
Member	Dr Morris Zwi MBBCh FRCPsych	Honorary Consultant Psychiatrist, South West London & St George's NHS Mental Health Trust

Membership of the CHM's Highly Personalised Medicines Expert Working Group (HPMEWG, formerly Cancer Vaccines EWG)

Post	Name and title	Affiliations
Chair	Professor Sir Munir Pirmohamed MB ChB (Hons) PhD FRCP FRCP (Edin) FBPhS, FFPM (Hon) FMedSci	David Weatherall Chair of Medicine, University of Liverpool, NHS Chair of Pharmacogenetics, Director of the Wolfson Centre for Personalised Medicine, Director of the Centre for Drug Safety Science
Lay Member	Mrs Julia Cons	
Member	Professor Cameron Alexander CChem, FRSC, FHEA	Professor of Polymer Therapeutics, Division of Molecular Therapeutics and Formulation, School of Pharmacy, University of Nottingham
Member	Dr Robert Andrews SFHEA FHEA	Senior Lecturer Data Hub at Heath, Cardiff
Member	Dr Colin Brown PhD FRCPPath	Consultant Clinical Scientist -Head of H&I Laboratory Colindale NHS Blood and Transplant
Member	Professor Robert Brown BSc PhD	Emeritus Professor of Translational Oncology, Department of Surgery & Cancer, Imperial College London
Member	Dr Peter Buckle FRSPH, FIEHF, FIEA, C.ErgHF	Principal Research Fellow, NIHR London In Vitro Diagnostics Co-operative Department of Surgery and Cancer, Faculty of Medicine, Imperial College London
Member	Professor Tom Clutton-Brock MBE MB ChB FRCP FRCA FFICM	Director, Medical Devices Testing and Evaluation Centre, Clinical Director, NIHR HealthTech Research Centre in Devices, Digital and Robotics, Chair, NICE Interventional Procedures Advisory Committee, Associate Medical Director, University Hospitals Birmingham NHS Foundation Trust, Professor of Anaesthesia & Intensive Care Medicine, University of Birmingham, Chair of the interim Devices Committee
Member	Professor Jamie Coleman MD MA (Med Ed) FRCP FBPhS	Consultant Physician, University Hospitals Birmingham NHS Foundation Trust and Honorary Professor in Clinical Pharmacology and Medical Education, University of Birmingham

Member	Professor Ann Daly BA PhD FBPhS	Professor of Pharmacogenetics, Faculty of Medical Sciences, Newcastle University
Member	Professor Jon Deeks PhD CStat FMedSci	Professor of Biostatistics, Department of Applied Health Science, College of Medicine and Health, University of Birmingham
Member	Dr Vasantha Gowda MBBS FRCPCH MSc	Paediatric Neurology Consultant & Paediatric Neuromuscular Service lead at Evelina London Children's Hospital, Honorary Senior Lecturer, King's College Hospital
Member	Dr Brendan Fish ⁷⁷ BSc PhD	Director of Biologics & RNA Centre of Excellence
Member	Dr Alan Hodgkinson BSc (Hons), DPhil.	Senior Lecturer, King's College London
Member	Dr Larissa Kerecuk FRCPCH	Consultant Paediatric Nephrologist, Birmingham Women's and Children's NHS Foundation Trust
Member	Professor Eric Lim MB ChB MD MSc FRCS(C-Th)	Consultant Thoracic Surgeon, Royal Brompton Hospital, Professor of Thoracic Surgery, Imperial College London
Member	Mr Robert Lowe BPharm FRPharmS	Practising Hospital Pharmacist, Specialist Pharmacy Services - East of England
Member	Professor Alan McIntyre PhD	Director Centre for Cancer Science, Biodiscovery Institute, School of Medicine, University of Nottingham
Member	Dr Alisdair McNeill PhD FRCP (Edin) DCH FHEA	Senior Clinical Lecturer in Neurogenetics & Hon Consultant Clinical Geneticist and Associate Director of Student Affairs (Intercalation) & Editor-in-Chief European Journal of Human Genetics
Member	Dr David Millrine PhD	Translational Immunology Team lead, CRUK Cancer Biomarker Centre, University of Manchester
Member	Professor Serena Nik-Zainal	MA MBBChir MRCP PhD FMedSci NIHR Research Professor, Professor of Genomic Medicine & Bioinformatics, Department of Medical Genetics, University of Cambridge Honorary Consultant in Clinical Genetics, Cambridge University Hospitals NHS Trust

⁷⁷ End of Appointment 13/06/2025

Member	Professor Christian Ottensmeier MD, PhD, FRCP	Professor of Molecular and Clinical Cancer Medicine, University of Liverpool
Member	Professor Sandosh Padmanabhan ⁷⁸ MBBS MD PhD FRCP(Glasg) FRCP(Edin) FBPhS FBIHS	Professor of Cardiovascular Genomics and Therapeutics, University of Glasgow
Member	Professor Poulam Patel PhD, MBBS, FRCP	Professor of Clinical Oncology, University of Nottingham
Member	Professor Yvonne Perrie BSc PhD	Professor in Drug Delivery within the Strathclyde Institute of Pharmacy and Biomedical Sciences
Member	Professor Shirley Price MSc, PhD, FBTS, FRSB, ERT, FHEA, FRSC, MBPharmacolSoc	Emerita Professor of Toxicology, University of Surrey Visiting Professor of Toxicology, University of Hertfordshire Honorary Professor of Toxicology, UKHSA
Member	Professor Carlo Rinaldi MA MD PhD	Professor of Molecular and Translational Neuroscience, Consultant Neurologist, University of Oxford
Member	Professor James Spicer FRCP, PhD	Professor of Experimental Cancer Medicine, King's College London; Consultant in Medical Oncology, Guy's & St Thomas' NHS Foundation Trust
Member	Professor Nigel Stallard BA MSc PhD	Professor of Medical Statistics Director Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry
Member	Professor Kevin M G Taylor BPharm PhD FRPharmS	Emeritus Professor of Clinical Pharmaceutics, UCL School of Pharmacy, London
Member	Dr Robin Thorpe BSc PhD FRCPPath	Retired, Head, Division of Biotherapeutics, National Institute for Biological Standards and Control (NIBSC) & Member of the Clinical Trials, Biologicals & Vaccines Expert Advisory Group (CTBVEAG)
Member	Dr David Turner PhD FRCPPath	H&I Laboratory, Scottish National Blood Transfusion Service, Royal Infirmary of Edinburgh
Member	Professor Marc Turner MB ChB PhD MBA FRCP FRCPPath FRSE	Director, Scottish National Blood Transfusion Service

⁷⁸ Appointed 01/07/2025

Member	Professor Christopher Weir BSc MSc PhD FRSS Cstat	Professor of Medical Statistics & Clinical Trials, Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh & Member of Commission on Human Medicines (CHM)
Member	Professor Anthony Williams BSc MSc MRCP, FRCPath, PhD	Professor of Translational Medicine and Honorary Consultant in Clinical Immunology and Allergy, University of Southampton and University Hospital Southampton NHS Trust
Member	Professor Christopher Yau MA MEng DPhil	Professor of Artificial Intelligence, Nuffield Department of Women's & Reproductive Health, University of Oxford and Health Data Research UK
Member	Professor Ly-Mee Yu BSc MSc DPhil	Professor of Clinical Trials and Biostatistics, Deputy Director Academic of Primary Care Clinical Trials Unit, Nuffield Department of Primary Care Health Sciences, University of Oxford

Membership the Real World Data Expert Working Group (RWD EWG)

Post	Name and title	Affiliations
Chair	Professor Deborah Ashby OBE FMedSci	Interim Dean of the Faculty of Medicine, Imperial College London
Member	Professor Janet Darbyshire CBE MB ChB FMedSci FRCP FFPH FRSS (Hon)	Emeritus Professor of Epidemiology, University College London
Member	Dr J Colin Forfar BSc(Hons) MA(Oxon) MD PhD FRCP FRCPE	Retired Consultant Physician and Cardiologist, John Radcliffe Hospital, Oxford
Member	Professor Peter Hall MB ChB MRCP PhD	Professor and Honorary Consultant in Medical Oncology
Member	Dr Daniel Hawcutt BSc (Hons) MB ChB (Hons) MD MRCPCH	Senior Lecturer in Paediatric Clinical Pharmacology, Women's and Children's Health, Institute of Translational Medicine, University of Liverpool, Member of Pharmacovigilance Expert Advisory Group (PEAG) and Member of Paediatric Medicines Expert Advisory Group (PMEAG)
Member	Professor Sarah Meredith	Professor of Clinical Trials, MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, Invited Expert of the Commission on Human Medicines (CHM)
Member	Professor Sir Munir Pirmohamed MB ChB (Hons) PhD FRCP FRCP (Edin) FBPhS, FFPM (Hon) FMedSci	David Weatherall Chair of Medicine, University of Liverpool, NHS Chair of Pharmacogenetics, Director of the Wolfson Centre for Personalised Medicine, Director of the Centre for Drug Safety Science, Chair of the Commission on Human Medicines (CHM)
Member	Professor Christopher Weir BSc (Hons) PhD MSc FRSS C.Stat	Personal Chair in Medical Statistics and Clinical Trials, Usher Institute, University of Edinburgh

ANNEX A - DECLARATION OF INTERESTS

Commission on Human Medicines, Commission's Expert Advisory Groups, Expert Working Groups and ad hoc groups members have declared current personal and non-personal interests in the pharmaceutical industry as follows:

Member	Committee(s)	Interest Type	Company / Organisation / Sponsor	Nature of Interest	Current	Additional Information
Aditya Sharma	NPPEAG, ARMEWG	Personal	NIL	N/A	N/A	
Aditya Sharma	NPPEAG, ARMEWG	Non-Personal	Lundbeck	Unrestricted medical educational grant towards a study	No	
Afzal Mohammed	CPSEAG	Personal	Aston Particle Technologies	Shares, Consultancy	Yes	
Afzal Mohammed	CPSEAG	Non-Personal	Catalent Pharma	Research Grant	Yes	
Afzal Mohammed	CPSEAG	Non-Personal	Colorcon Ltd	Research Grant	No	
Afzal Mohammed	CPSEAG	Non-Personal	MaxBiotech Ltd	Research Grant	Yes	
Afzal Mohammed	CPSEAG	Non-Personal	Proveca Ltd	Research Grant	Yes	
Afzal Mohammed	CPSEAG	Non-Personal	Eye Docs Ltd	Research Grant	Yes	
Afzal Mohammed	CPSEAG	Non-Personal	Quest Healthcare	Research Grant	Yes	
Al Constant	ARMEWG	Personal	NIL	N/A	N/A	
Al Constant	ARMEWG	Non-Personal	NIL	N/A	N/A	
Alan Hodgkinson	HPMEWG	Personal	NIL	N/A	N/A	
Alan Hodgkinson	HPMEWG	Non-Personal	NIL	N/A	N/A	

Alan Hodgkinson	HPMEWG	Additional				Other person: employed by a pharmaceutical company in global regulatory affairs, neurology
Alan McIntyre	HPMEWG	Personal	NIL	N/A	N/A	
Alan McIntyre	HPMEWG	Non-Personal	NIL	N/A	N/A	
Alana Adams	PEAG	Personal	NIL	N/A	N/A	
Alana Adams	PEAG	Non-Personal	NIL	N/A	N/A	
Alisdair McNeill	HPMEWG	Personal	NIL	N/A	N/A	
Alisdair McNeill	HPMEWG	Non-Personal	NIL	N/A	N/A	
Alison Mears	ARMEWG	Personal	NIL	N/A	N/A	
Alison Mears	ARMEWG	Non-Personal	NIL	N/A	N/A	
Alison Mears	ARMEWG	Additional				In contact with the individual who set up and manages the RxISK.org website (an independent website launched in 2012 to support patients who have been affected by side effects of medications in particular, but not only, SSRIs). www.rxisk.org. Refers patients, provides link ups with other healthcare providers interested in PSSD and discusses ongoing and future research collaborations. In 2024 the Rxisk group funded a set of Von Frey filaments in clinic, to better assess the sensory difficulties our patients are experiencing.

Amanda Adler	CHM, CDRRA EAG	Personal	NIL	N/A	N/A
Amanda Adler	CHM, CDRRA EAG	Non- Personal	NIL	N/A	N/A
Amanda Adler	CHM, CDRRA EAG	Conference s/Scientific Meetings	Sponsor: Lilly	Academic participant on the steering committee of this 'TRIUMPH' trial for the unlicensed compound Retatrutide. Declined all honorarium related to this, including indirectly (i.e. to my employing institution). Receive travel support when meetings are face-to face. Methodology – no financial personal gain. No products discussed.	
Amanda Adler	CHM, CDRRA EAG	Additional			Does not accept income from the device or pharmaceutical industry. Work for Oxford University, which does receive support from the pharmaceutical industry.
Amine Boualem	CDRRA EAG	Personal	NIL	N/A	N/A
Amine Boualem	CDRRA EAG	Non- Personal	NIL	N/A	N/A
Andrew Freedman	IEAG	Personal	NIL	N/A	N/A
Andrew Freedman	IEAG	Non- Personal	NIL	N/A	N/A
Angela Thomas	ARMEWG	Personal	Moderna	Participant in clinical trial	Yes
Angela Thomas	ARMEWG	Non- Personal	NIL	N/A	N/A
Anita Simonds	CDRRA EAG	Personal	NIL	N/A	N/A
Anita Simonds	CDRRA EAG	Non- Personal	NIL	N/A	N/A

Anjan Dhar	GRIDEAG	Personal	Takeda UK	Consultancy and Advisory Role, speaker fees	No	
Anjan Dhar	GRIDEAG	Personal	Johnson & Johnson	Consultancy, advisory and speaker fees	No	
Anjan Dhar	GRIDEAG	Personal	Dr Falk Pharma UK	Consultancy, advisory and speaker fees	No	
Anjan Dhar	GRIDEAG	Personal	Alfasigma	Advisory role, speaker fees	No	
Anjan Dhar	GRIDEAG	Personal	Abbvie UK	Speaker Fees and Chair	No	
Anjan Dhar	GRIDEAG	Personal	Lilly	Consultancy, advisory and speaker fees	No	
Anjan Dhar	GRIDEAG	Personal	Pharmacosmos	Speaker Fees and Hospitality	No	
Anjan Dhar	GRIDEAG	Personal	Tillotts UK	Speaker Fees and Chair	No	
Anjan Dhar	GRIDEAG	Non-Personal	NIL	N/A	N/A	
Anjan Dhar	GRIDEAG	Conference s/Scientific Meetings	Sponsor: Johnson and Johnson - ECCO 2025	Full registration, travel and accommodation	No	
Anjan Dhar	GRIDEAG	Conference s/Scientific Meetings	Sponsor: Celltrion - United European Gastroenterology Week	Full registration, travel and accommodation	No	
Anjum Khan	OHEAG	Personal	Astellas	Fee-Paid Work	No	
Anjum Khan	OHEAG	Personal	Jazz	Consultancy	No	
Anjum Khan	OHEAG	Personal	Medac	Fee-Paid Work	No	
Anjum Khan	OHEAG	Personal	Novartis	Fee-Paid Work	No	
Anjum Khan	OHEAG	Personal	Otsuka	Consultancy	No	
Anjum Khan	OHEAG	Personal	Servier	Fee-Paid Work	No	
Anjum Khan	OHEAG	Personal	Synairgen	Consultancy	Yes	
Anjum Khan	OHEAG	Conference s/Scientific Meetings	Medac	Conference registration & travel.	No	European Society for Blood & Marrow Transplantation Meeting 2025
Anjum Khan	OHEAG	Conference s/Scientific Meetings	Servier	Conference registration, travel, accommodation	No	
Anjum Khan	OHEAG	Non-Personal	Novartis	Fee-Paid Work	No	

Anjum Khan	OHEAG	Non-Personal	AOP	Fee-Paid Work	No
Anjum Khan	OHEAG	Non-Personal	GlaxoSmithKline	Fee-Paid Work	No
Ann Daly	PEAG, HPMEWG	Personal	NIL	N/A	N/A
Ann Daly	PEAG, HPMEWG	Non-Personal	NIL	N/A	N/A
Anna Schultze	PEAG	Personal	NIL	N/A	N/A
Anna Schultze	PEAG	Non-Personal	GSK	A grant for research into pharmacoepidemiology methods received by department at LSHTM currently supports salary as an employee of LSHTM, as well as the studentship of two PhD students.	Yes
Anthony Avery	ARMEWG	Personal	NIL	N/A	N/A
Anthony Avery	ARMEWG	Non-Personal	NIL	N/A	N/A
Anthony Avery	ARMEWG	Additional			National Clinical Director for Prescribing for NHS England. Clinical academic and the University of Nottingham receives income from non-commercial research grants held. These grants relate mainly to prescribing and patient safety.
Anthony Williams	CHM, GRIDEAG, HPMEWG	Personal	NIL	N/A	N/A
Anthony Williams	CHM, GRIDEAG, HPMEWG	Non-Personal	NIL	N/A	N/A
Arianna Di Florio	ARMEWG	Personal	NIL	N/A	N/A
Arianna Di Florio	ARMEWG	Non-Personal	NIL	N/A	N/A
Asha Kasliwal	MWHEAG	Personal	NIL	N/A	N/A
Asha Kasliwal	MWHEAG	Non-Personal	NIL	N/A	N/A

Asha Odedra	CDRRA EAG	Personal	NIL	N/A	N/A
Asha Odedra	CDRRA EAG	Non-Personal	NIL	N/A	N/A
Ashley Liew	PMEAG	Conference s/Scientific Meetings	Flynn Pharma	Expenses	
Ashley Liew	PMEAG	Personal	NIL	N/A	N/A
Ashley Liew	PMEAG	Non-Personal	NIL	N/A	N/A
Barbara Conway	CPSEAG	Personal	NIL	N/A	N/A
Barbara Conway	CPSEAG	Non-Personal	T & R (Stada)	Sponsorship of University educational activities	
Barbara Conway	CPSEAG	Conference s/Scientific Meetings	Sponsor: Journal of Woundcare - Wounds Week	Honorarium	
Barry Miller	NPPEAG, ARMEWG	Personal	NIL	N/A	N/A
Barry Miller	NPPEAG, ARMEWG	Non-Personal	NIL	N/A	N/A
Barry Miller	NPPEAG, ARMEWG	Additional	Faculty of Pain Medicine	Elected Board Member of the Faculty of Pain Medicine (FPM) (until March 2025) (and former Dean)	Elected Board Member of the Faculty of Pain Medicine (FPM) (until March 2025) (and former Dean)
Barry Miller	NPPEAG, ARMEWG	Additional	Royal College of Anaesthetists Ethics Committee	Member of the Royal College of Anaesthetists Ethics Committee	Member of the Royal College of Anaesthetists Ethics Committee prescribing
Ben Forbes	CPSEAG	Personal	NIL	N/A	N/A
Ben Forbes	CPSEAG	Non-Personal	AstraZeneca	PhD student project funding	
Ben Forbes	CPSEAG	Non-Personal	Novartis	PhD student project funding	
Ben Forbes	CPSEAG	Non-Personal	Biotherapy Services	PhD student project funding	
Ben Uttenthal	OHEAG	Personal	Gilead (Kite)	Sponsorship for conference attendance, speaker fees, honoraria for advisory board	

Ben Uttenthal	OHEAG	Personal	Sartorius	Consultancy for product development; potential support for academic programme	
Ben Uttenthal	OHEAG	Personal	Swarm Oncology	Consultancy	
Ben Uttenthal	OHEAG	Personal	Abbvie	Sponsorship for conference attendance; speaker fees	
Ben Uttenthal	OHEAG	Personal	Autolus	Principal investigator - sponsorship of clinical trial	
Ben Uttenthal	OHEAG	Conference s/Scientific Meetings	Sponsor: Abbvie - International Conference on Malignant Lymphoma (ICML)	Sponsorship of travel/registration fees and provision of accommodation	
Ben Uttenthal	OHEAG	Non-Personal	Autolus	Principal investigator - Sponsorship of clinical trial	
Ben Uttenthal	OHEAG	Non-Personal	Kyverna	Principal investigator - Sponsorship of clinical trial	
Brendan Fish	HPMEWG	Personal	NIL	N/A	N/A
Brendan Fish	HPMEWG	Non-Personal	NIL	N/A	N/A
Brian Angus	IEAG	Personal	NIL	N/A	N/A
Brian Angus	IEAG	Non-Personal	NIL	N/A	N/A
Caitlin Dean	MWHEAG	Personal	NIL	N/A	N/A
Caitlin Dean	MWHEAG	Non-Personal	NIL	N/A	N/A
Cameron Alexander	HPMEWG	Personal	Aqdot Ltd	Co-inventor on patent filed in June 2025 for formulations related to personalisable nucleic acid therapeutics	
Cameron Alexander	HPMEWG	Non-Personal	AstraZeneca	Co-funder (with EPSRC) of Centre for Doctoral Training research grant funding for School of Pharmacy in Nottingham	
Cameron Alexander	HPMEWG	Non-Personal	GSK	Co-funder (with EPSRC) of Centre for Doctoral Training research	

				grant funding for School of Pharmacy in Nottingham
Cameron Alexander	HPMEWG	Non-Personal	Pfizer	Co-funder (with EPSRC) of Centre for Doctoral Training research grant funding for School of Pharmacy in Nottingham
Cameron Alexander	HPMEWG	Non-Personal	Quotient	Co-funder (with EPSRC) of Centre for Doctoral Training research grant funding for School of Pharmacy in Nottingham and UCL and InnovateUK project “SUMMIT – SUstainable Manufacture of Macromolecular Intracellular Therapeutics”
Cameron Alexander	HPMEWG	Non-Personal	Upperton	Co-funder (with EPSRC) of Centre for Doctoral Training research grant funding for School of Pharmacy in Nottingham
Cameron Alexander	HPMEWG	Non-Personal	Croda	Co-funder (with EPSRC) of Centre for Doctoral Training research grant funding for School of Pharmacy in Nottingham
Cameron Alexander	HPMEWG	Non-Personal	Arcinova	Co-funder (with EPSRC) of Centre for Doctoral Training research grant funding for School of Pharmacy in Nottingham
Cameron Alexander	HPMEWG	Non-Personal	Kindeva	Co-funder (with EPSRC) of Centre for Doctoral Training research grant funding for School of Pharmacy in Nottingham
Cameron Alexander	HPMEWG	Non-Personal	Nemauro	Co-funder (with EPSRC) of Centre for Doctoral Training research grant funding for School of Pharmacy in Nottingham
Cameron Alexander	HPMEWG	Non-Personal	Aqdot	Partner company for InnovateUK project “Supramolecular RNA

				therapeutics (SMRTs) - developing tunable formulations with scale-independent manufacture” and “SUMMIT – SUstainable Manufacture of Macromolecular Intracellular Therapeutics”	
Cameron Alexander	HPMEWG	Non-Personal	Centillion	Partner company for InnovateUK project “Supramolecular RNA therapeutics (SMRTs) - developing tunable formulations with scale-independent manufacture” and “SUMMIT – SUstainable Manufacture of Macromolecular Intracellular Therapeutics”	
Carlo Rinaldi	HPMEWG	Personal	Biogen	Consultancy	
Carlo Rinaldi	HPMEWG	Personal	Novartis	Grant	
Carlo Rinaldi	HPMEWG	Personal	Biomarin	Grant	
Carlo Rinaldi	HPMEWG	Non-Personal	NIL	N/A	
Carol Paton	ARMEWG	Personal	Eli Lilly	One-off consultancy board relating to the potential use of these medications for addictions.	
Carol Paton	ARMEWG	Non-Personal			
Caroline Jones	PMEAG	Personal	NIL	N/A	N/A
Caroline Jones	PMEAG	Non-Personal	NIL	N/A	N/A
Caroline Wilson	ARMEWG	Personal	NIL	N/A	N/A
Caroline Wilson	ARMEWG	Non-Personal	NIL	N/A	N/A
Catrin Barker	PMEAG	Personal	NIL	N/A	N/A
Catrin Barker	PMEAG	Non-Personal	NIL	N/A	N/A
Celia Moss	GRIDEAG	Personal	NIL	N/A	N/A
Celia Moss	GRIDEAG	Non-Personal	NIL	N/A	N/A

Celia Moss	GRIDEAG	Additional			Trustee of National Eczema Society
Celia Moss	GRIDEAG	Additional			Member of British Association of Dermatologists
Chris Goldring	CTBVEAG	Personal	NIL	N/A	N/A
Chris Goldring	CTBVEAG	Non-Personal	Innovative Medicines Initiative Project: Transbioline 7 Pharmaceutical companies: Pfizer, MSD, Roche, Eli Lilly, Novartis, Janssen, Sanofi-Aventis	Grant	
Chris Goldring	CTBVEAG	Non-Personal	RedX Pharma	Consultancy paid into University of Liverpool research account	
Christian Ottensmeier	HPMEWG	Personal	NIL	N/A	N/A
Christian Ottensmeier	HPMEWG	Non-Personal	NIL	N/A	N/A
Christina Yap	CTBVEAG	Personal	Faron Pharmaceuticals	Independent Statistical Consultant	
Christina Yap	CTBVEAG	Personal	Duke Street	Research grant as statistical methodologist/advisor	
Christina Yap	CTBVEAG	Personal	Merck	Independent Statistical Consultant; Providing patient-reported outcomes methodology expert advice	
Christina Yap	CTBVEAG	Personal	Trogenix	Independent Statistical Consultant	
Christina Yap	CTBVEAG	Non-Personal	AstraZeneca	Trial grant (co-investigator)	
Christina Yap	CTBVEAG	Non-Personal	Plexxikon	Trial grant (co-investigator)	
Christopher Weir	CHM, RWD EWG, HPMEWG	Personal	NIL	N/A	N/A

Christopher Weir	CHM, RWD EWG, HPMEWG	Non- Personal	AB Science	DSMB membership for three trials (in ALS, mastocytosis and progressive MS), plus advice on masitinib regulatory submissions, resulting in income to department	N/A
Christopher Weir	CHM, RWD EWG, HPMEWG	Non- Personal	Eli Lilly	Research grant to institution (co – applicant)	N/A
Christopher Yau	HPMEWG	Personal	NIL	N/A	N/A
Christopher Yau	HPMEWG	Non- Personal	NIL	N/A	N/A
Claire Stewart	CHM	Personal	NIL	N/A	N/A
Claire Stewart	CHM	Conference s/Scientific Meetings	NIL	N/A	N/A
Claire Stewart	CHM	Non- Personal	NIL	N/A	N/A
Claire Stewart	CHM	Additional			University of Nottingham - From 2020 until now, Dean and Head of School of Medicine University of Nottingham. Responsible for all the researchers within the school of medicine and, therefore, a large research portfolio.
Claire Stewart	CHM	Additional			Universitas 21 from 2024 - onwards The chair of the Universitas 21 medicine discipline group. This is an international group of 20 research active universities who mentor each other and collaborate on research and teaching efforts.
Clare Pain	PMEAG	Personal	NIL	N/A	N/A
Clare Pain	PMEAG	Non- Personal	NIL	N/A	N/A

Clare Pain	PMEAG	Additional				Currently have CTIMPS open at our site with following companies (role stated): Abbvie – site PI for Risankizumab in JIA Amgen – UK CI for paediatric Behcet’s trial of apremilast (ongoing) Lilly – ixekizumab in JIA – in follow-up (sub-investigator) Roche – Obinutuzumab in lupus nephritis (sub-investigator) AstraZeneca – anifrolumab in paediatric lupus (sub-investigator)
Colin Brown	HPMEWG	Personal	NIL	N/A	N/A	
Colin Brown	HPMEWG	Non-Personal	NIL	N/A	N/A	
Colin Forfar	RWD EWG	Personal	NIL	N/A	N/A	
Colin Forfar	RWD EWG	Non-Personal	NIL	N/A	N/A	
Daniel Hawcutt	PEAG, PMEAG, RWD EWG	Personal	STERITAS	Member of Advisory Panel		Member of their clinical consultancy group providing advice on paediatric uses for this product. A single meeting during 2025
Daniel Hawcutt	PEAG, PMEAG, RWD EWG	Non-Personal	Various	Director of the NIHR Alder Hey Clinical Research Facility. This has a range of commercial research studies at any one time, but does not receive any personal payment for the studies or for taking a PI or lx role (the money is used within the clinical research division at		

				Alder Hey to support research infrastructure and staffing).
Daniel Hawcutt	PEAG, PMEAG, RWD EWG	Non-Personal	University of Liverpool and Alder Hey Children's Hospital	Appointed director of the Liverpool Institute of Child Health and wellbeing, and will lead the strategic direction and implement the research strategy. This will involve doing studies on academic and commercial medicines – will not get paid directly for this, but income will support the institute.
Daniel Lumsden	PMEAG	Personal	Acadia	Consultancy fees – paid directly to Guy's and St Thomas' NHS Foundation Trust
Daniel Lumsden	PMEAG	Conference s/Scientific Meetings	Expenses (travel and accommodation) paid to support attendance at meeting as invited speaker	01/07/2025
Daniel Lumsden	PMEAG	Non-Personal	NIL	N/A
Daniel Lumsden	PMEAG	Additional		Immediate family member is Head of Regulatory Science and Policy, EU/AMME Sanofi (Global Regulatory affair).
Darragh Murnane	CPSEAG	Personal	Informix Pharma Ltd. IP29 5DA	Personal, Founder, Director, Shareholder
Darragh Murnane	CPSEAG	Personal	Merxin Ltd.	Non-specific, Scientific Advisory Board Fees
Darragh Murnane	CPSEAG	Non-Personal	Bespak Ltd.	Funding for collaborative research, 2 PhD projects and consultancy performed through University of Hertfordshire

Darragh Murnane	CPSEAG	Non-Personal	Merxin Ltd.	Funding for PhD studentship performed through University of Hertfordshire
Darragh Murnane	CPSEAG	Non-Personal	Philips Respironics	Loaned Equipment at University of Hertfordshire
Darragh Murnane	CPSEAG	Non-Personal	Capitainer Ab	Sponsored research student at University of Hertfordshire
Darragh Murnane	CPSEAG	Non-Personal	Informix Pharma Ltd.	Consultancy and travel costs for services provided through University of Hertfordshire on various projects
Darragh Murnane	CPSEAG	Conference s/Scientific Meetings	Merxin Ltd.	Hospitality after Advisory Board
Darragh Murnane	CPSEAG	Conference s/Scientific Meetings	Vectura Ltd.	Travel expenses ahead for company seminar
Darragh Murnane	CPSEAG	Conference s/Scientific Meetings	Lupin Inc	Lunch after company seminar
Darragh Murnane	CPSEAG	Conference s/Scientific Meetings	Sponsor: Merxin Ltd - RDD 2025	Hospitality at RDD 2025 Conference
Darragh Murnane	CPSEAG	Conference s/Scientific Meetings	Sponsor: Merxin Ltd - DDL 2025	Hospitality at DDL 2025 Conference
Darragh Murnane	CPSEAG	Conference s/Scientific Meetings	Transpire Bio Inc	Travel expenses for company seminar
Darragh Murnane	CPSEAG	Additional		Founder and Board Member of Informix Pharma Ltd. and current CEO of Wickham Micro Ltd. Wickham Micro Ltd. provide contract analytical services to the pharmaceutical industry

Darren Ashcroft	PEAG	Personal	NIL	N/A	N/A
Darren Ashcroft	PEAG	Non-Personal	LEO Foundation, Bristol Myers Squibb, Boehringer Ingelheim, Johnson & Johnson (Janssen), Almirall, Takeda Pharmaceutical, UCB	Research grant to support the development of the Global Psoriasis Atlas	
David Crundwell	CHM	Personal	NIL	N/A	N/A
David Crundwell	CHM	Non-Personal	NIL	N/A	N/A
David Crundwell	CHM	Additional	Chair of NHS CPAG (Clinical Priorities Advisory Group)	Chair of NHS CPAG	
David Crundwell	CHM	Additional	JRCPTB SAC for Acute Internal Medicine	Lay Board Member - Unpaid	Unpaid lay member
David Crundwell	CHM	Additional	JRCPTB SAC for Pharmaceutical Medicine	Lay Board Member - Unpaid	Unpaid lay member
David Crundwell	CHM	Additional	NIHR sponsored research project Sequence Digital	Lay Board Member - Unpaid	Unpaid lay member
David Dockrell	CHM, IEAG	Personal	NIL	N/A	N/A
David Dockrell	CHM, IEAG	Non-Personal	Adiso Therapeutics, Inc GlaxoSmithKline Pfizer Inc Chan Zuckerberg Initiative Santerus AG	Industry companies for whom the academic centre Director of (Centre for Inflammation Research, University of Edinburgh) has current or recent industry sponsorship through grants or other support to investigators.	

			IPInc Intercept Pharmaceuticals inc Gene One Genentech Inc Stryker International Sanofi Pasteur MSD Limited GlaxoSmithKline UCBC UCB BioPharma Srl Novartis Pharma AG Galecto Biotech AB Corin Ltd Scottish Power AstraZeneca Canon Gene cell catapult	Other than those outlined above these are not direct to me
David Dockrell	CHM, IEAG	Non-Personal	GSK	Access to Nrf2 agonist compounds for research by own personal group and collaborators. Commitment to continue to provide further Nrf2 agonist compounds on ongoing MRC Programme grant awarded May 2022 and commenced in December 2022. No direct financial benefit, in kind contribution of compounds. and commenced in December 2022. No direct financial benefit, in kind contribution of compounds.
David Dockrell	CHM, IEAG	Non-Personal	AstraZeneca	Advisor on a research project and have reviewed and been included

				on work presented but not published to date. Compounds involved in assays listed. No financial benefit Historical link but company could decide to publish in future. Historical link but papers not yet published if company even decide to publish.	
David Dockrell	CHM, IEAG	Non-Personal	Moderna, Infex Therapeutics, Cell and Gene Therapy Catapult, PLEX	Lead an MRC CoRE application to interview January 2025, but not funded. The work has led to further ongoing funding submission. The named companies were named as potential partners in the bid and have been approached about involvement in follow on bids. They state they will share expertise, provide training, advise on potential translational strategies and give access to their product pipeline or in case of PLEX to their AI platform to help the academic partners to develop their findings as host based immunotherapeutics to retune innate immune responses to infection.	
David Dockrell	CHM, IEAG	Non-Personal	Amoytop Biotech	GMP EP/CP grade for use in pre-clinical models of infection/vaccination. Company providing materials but no personal benefits, unlikely to be primary investigator but host the primary investigator in research centre as a co-investigator.	
David Hunt	CHM, NPPEAG	Personal	NIL	N/A	N/A

David Hunt	CHM, NPPEAG	Conference s/Scientific Meetings	Sponsor: Cabeletta Bio, Autolus, Bristol Myers Squibb	Attendance at meeting (no expenses, no hospitality)	
David Hunt	CHM, NPPEAG	Conference s/Scientific Meetings	Sponsor: Moderna	Attendance at meeting (no expenses, no hospitality)	
David Hunt	CHM, NPPEAG	Non- Personal	Autolus	Investigator, AUTO1-MS1 A single-arm, open-label, phase I study to determine the safety, tolerability, and preliminary efficacy of obe-cel in participants with refractory progressive forms of multiple sclerosis	
David Hunt	CHM, NPPEAG	Non- Personal	Moderna	UK Chief Investigator mRNA-1195- P201 study (Horizon trial of EBV vaccination in multiple sclerosis)	
David Hunt	CHM, NPPEAG	Additional			Spoken at a number of multiple sclerosis meetings which have received sponsorship from the pharmaceutical industry (unremunerated). Have given invited lectures to Roche pharmaceuticals at their Headquarters in Basel (self funded trip, unremunerated) Professor Hunt leads NHS multiple sclerosis services within the Anne Rowling Clinic in Edinburgh. The Anne Rowling Clinic is supported by a philanthropic gift from JK Rowling to the University of Edinburgh.
David Kessler	ARMEWG	Personal	NIL	N/A	N/A

David Kessler	ARMEWG	Non-Personal	NIL	N/A	N/A
David Millrine	HPMEWG	Personal	NIL	N/A	N/A
David Millrine	HPMEWG	Non-Personal	NIL	N/A	N/A
David Moore	CHM	Personal	NIL	N/A	N/A
David Moore	CHM	Non-Personal	NIL	N/A	N/A
David Owens	NPPEAG, ARMEWG	Personal	NIL	N/A	N/A
David Owens	NPPEAG, ARMEWG	Conference s/Scientific Meetings	NIL	N/A	N/A
David Owens	NPPEAG, ARMEWG	Non-Personal	NIL	N/A	N/A
David Taylor	ARMEWG	Personal	Janssen	Research funding, lectures	
David Taylor	ARMEWG	Personal	428 Pharma	Shares	
David Taylor	ARMEWG	Personal	Myogenes	Shares	
David Taylor	ARMEWG	Personal	Saladax	Shares	
David Taylor	ARMEWG	Non-Personal	NIL	N/A	N/A
David Turner	HPMEWG	Personal	NIL	N/A	N/A
David Turner	HPMEWG	Non-Personal	NIL	N/A	N/A
Debashis Sarker	OHEAG	Personal	AstraZeneca	Advisory Board	
Debashis Sarker	OHEAG	Personal	Servier	Invited speaker, advisory board	
Debashis Sarker	OHEAG	Personal	Eisai	Invited speaker, advisory board	
Debashis Sarker	OHEAG	Personal	Ipsen	Invited speaker	
Debashis Sarker	OHEAG	Conference s/Scientific Meetings	Sponsor: Ipsen - European NET Society (ENETS) Annual Meeting	Travel, conference and hotel expenses	
Debashis Sarker	OHEAG	Conference s/Scientific Meetings	Sponsor: Servier - European Society Medical Oncology Annual Meeting	Travel, conference and hotel expenses	

Debashis Sarker	OHEAG	Non-Personal	UCB Biopharma	Research fellowship grants to KCL	
Deborah Ashby	RWD EWG	Personal	NIL	N/A	N/A
Deborah Ashby	RWD EWG	Non-Personal	NIL	N/A	N/A
Deborah Ashby	RWD EWG	Additional			Dean of the Faculty of Medicine from 2024 to date. Some staff hold grants, consultancies etc but no direct involvement in those.
Diana Wellesley	MWHEAG	Personal	NIL	N/A	N/A
Diana Wellesley	MWHEAG	Non-Personal	NIL	N/A	N/A
Ellie Gordon	ARMEWG	Personal	NIL	N/A	N/A
Ellie Gordon	ARMEWG	Non-Personal	NIL	N/A	N/A
Eric Lim	HPMEWG	Personal	Takeda	Consultancy	Yes
Eric Lim	HPMEWG	Personal	AstraZeneca	Consultancy	Yes
Eric Lim	HPMEWG	Personal	Boehringer Ingelheim	Consultancy	Yes
Eric Lim	HPMEWG	Personal	Medela	Consultancy	Yes
Eric Lim	HPMEWG	Personal	BeiGene	Consultancy	Yes
Eric Lim	HPMEWG	Personal	Roche	Consultancy	Yes
Eric Lim	HPMEWG	Personal	BMS	Consultancy	Yes
Eric Lim	HPMEWG	Personal	MDS	Consultancy	Yes
Eric Lim	HPMEWG	Personal	Johnson and Johnson (Ethicon)	Consultancy	Yes
Eric Lim	HPMEWG	Personal	Covidien / Medtronic	Consultancy	Yes
Eric Lim	HPMEWG	Personal	Sinapi	Consultancy	Yes
Eric Lim	HPMEWG	Non-Personal	Guardant Health		
Eric Lim	HPMEWG	Non-Personal	AstraZeneca		
Eric Lim	HPMEWG	Non-Personal	Lilly Oncology		

Eric Lim	HPMEWG	Non-Personal	Bayer	
Eric Lim	HPMEWG	Non-Personal	Medela	
Eric Lim	HPMEWG	Non-Personal	Johnson and Johnson (Ethicon)	
Eric Lim	HPMEWG	Non-Personal	Covidien / Medtronic	
Eric Lim	HPMEWG	Conference s/Scientific Meetings	Medela - ESTS	Expenses
Eric Lim	HPMEWG	Additional		My Cancer Companion Healthcare Companion Ltd Founder Patents issued: Imperial Innovations P57988GB P52435GB
Farzin Farzeneh	CTBVEAG	Personal	Apertina	Consultancy
Farzin Farzeneh	CTBVEAG	Personal	Dawn Therapeutics	Consultancy and Shares
Farzin Farzeneh	CTBVEAG	Personal	ViroCell Holdings Ltd	Appointed as the Chief Scientific Officer. Co-Founder and Share Holder
Farzin Farzeneh	CTBVEAG	Personal	King's College London	Part-time Professor of Molecular Medicine
Farzin Farzeneh	CTBVEAG	Personal	Guys Hospital NHS Trust	Qualified Person
Farzin Farzeneh	CTBVEAG	Personal	Great Ormond Street Hospital NHS Trust	Qualified Person
Farzin Farzeneh	CTBVEAG	Personal	University of Dresden	Trans-Campus Professor of Molecular Medicine, in partnership with King's College London
Farzin Farzeneh	CTBVEAG	Personal	Imperial College London	Visiting Professor of Molecular Medicine

Farzin Farzeneh	CTBVEAG	Personal	University College London	Honorary Professor of Molecular Medicine	
Farzin Farzeneh	CTBVEAG	Non-Personal	NIL	N/A	N/A
Federico Brucoli	CPSEAG	Personal	NIL	N/A	N/A
Federico Brucoli	CPSEAG	Non-Personal	NIL	N/A	N/A
Fergus Rugg-Gunn	NPPEAG	Personal	NIL	N/A	N/A
Fergus Rugg-Gunn	NPPEAG	Non-Personal	NIL	N/A	N/A
Fraz Mir	PEAG	Personal	BNF	Chair of BNF Formulary Committee	Honorarium
Fraz Mir	PEAG	Non-Personal	NIL	N/A	N/A
Fraz Mir	PEAG	Conference s/Scientific Meetings	AstraZeneca	They supported the conference with a grant and venue for meeting	
Geraint Davies	IEAG	Personal	NIL	N/A	N/A
Geraint Davies	IEAG	Non-Personal	NIL	N/A	N/A
Geraint Davies	IEAG	Additional	PanACEA clinical trials consortium, funded by the European and Developing Countries Clinical Trials Partnership		Academic partner to the PanACEA clinical trials consortium, funded by the European and Developing Countries Clinical Trials Partnership since 2017. Though the consortium has involved contact and collaboration with pharmaceutical partners, the role at the University of Liverpool is as a partner without budget supporting the clinical trials site at the College of Medicine in Blantyre, Malawi. University of Liverpool,

				University of Malawi College of Medicine and expert do not receive any funding from pharmaceutical collaborators as part of these activities. collaboration with pharmaceutical partners, the role at the University of Liverpool is as a partner without budget supporting the clinical trials site at the College of Medicine in Blantyre, Malawi. University of Liverpool, University of Malawi College of Medicine and expert do not receive any funding from pharmaceutical collaborators as part of these activities.
Geraint Davies	IEAG	Additional	UNITE4TB consortium, a new public-private partnership funded by the European Union Innovative Medicines Initiative and the European Federation of Pharmaceutical Industries	Academic partner to the UNITE4TB consortium since 2020, a new public-private partnership funded by the European Union Innovative Medicines Initiative and the European Federation of Pharmaceutical Industries until 2028. However, though this role involves engagement with industrial partners (GSK, Janssen, Evotech) in pre-competitive areas of research into TB drug development, these activities are fully supported by public funding from the EU and do not receive any funding from EFPIA or from

the individual industrial partners. Pharmaceutical Industries until 2028. However, though this role involves engagement with industrial partners (GSK, Janssen, Evotech) in pre-competitive areas of research into TB drug development, these activities are fully supported by public funding from the EU and do not receive any funding from EFPIA or from the individual industrial partners.

Geraint Davies	IEAG	Additional	Expert advisory meetings convened by GSK and Janssen			Attended expert advisory meetings relating to TB drug development convened by GSK and Janssen and received no payment or benefit (honorarium, expenses, hospitality)
Gerri Mortimore	CHM	Personal	NIL	N/A	N/A	
Gerri Mortimore	CHM	Non-Personal	NIL	N/A	N/A	
Gerri Mortimore	CHM	Conference s/Scientific Meetings	Sponsor: Gastrointestinal Nursing Journal (Mark Allen Group)	Train fares paid from Derby to London return and overnight accommodation		
Glyn Lewis	ARMEWG	Personal	NIL	N/A	N/A	
Glyn Lewis	ARMEWG	Non-Personal	NIHR	Research funding to UCL (employer) concerning pregabalin	N/A	
Glyn Lewis	ARMEWG	Non-Personal	UKRI	Research funding to UCL but not concerned with pharmaceutical agents		

Glyn Lewis	ARMEWG	Non-Personal	Wellcome Trust	Research funding to UCL but not concerned with pharmaceutical agents	
Glyn Lewis	ARMEWG	Non-Personal	MHRUK	Research funding to UCL but not concerned with pharmaceutical agents	
Guido Pieles	PMEAG	Personal	Pharmanovia	External Consultant Advisor	
Guido Pieles	PMEAG	Personal	Cardiac Health & Performance Ltd.	Paediatric and adult Sports Cardiology Consultancy, Director	
Guido Pieles	PMEAG	Personal	Enhanced	Chair of the External Medical Commission - consultancy	
Guido Pieles	PMEAG	Non-Personal	NIL	N/A	N/A
Hadar Zaman	CPSEAG	Personal	NIL	N/A	N/A
Hadar Zaman	CPSEAG	Non-Personal	NIL	N/A	N/A
Hannah Batchelor	CPSEAG	Personal	NIL	N/A	N/A
Hannah Batchelor	CPSEAG	Non-Personal	GSK	Grant awarded to support PhD student under supervision	
Hassan Kahal	CDRRA EAG	Personal	NIL	N/A	N/A
Hassan Kahal	CDRRA EAG	Non-Personal	NIL	N/A	N/A
Hassan Kahal	CDRRA EAG	Additional			Principal investigator and sub-investigator) on a number of commercial and non-commercial multi-centre clinical research trials related to obesity and diabetes conducted at the Diabetes research centre at North Bristol NHS Trust. Family member works for Amgen in drug development but this has no impact on clinical decision making. Started a private clinic in Sept 2025 with focus on

						managing people with obesity, diabetes, and PCOS. Received no personal payment, honoraria, or travel support from any pharmaceutical company.
Heather Wallace	CHM	Personal	NIL	N/A	N/A	
Heather Wallace	CHM	Non-Personal	NIL	N/A	N/A	
Heather Wallace	CHM	Additional	Medical Research Scotland			Chair of Medical Research Scotland, which fund PhD studentships, and each studentship has an external partner organisation (EPO). This can be industry or charity. The relationship is between the student, supervisor and university. Medical Research Scotland provides funds to the University who funds the student but has no relationship with the student or the EPO.
Hoo Kee Tsang	NPP EAG, ARMEWG	Personal	NIL	N/A	N/A	
Hoo Kee Tsang	NPP EAG, ARMEWG	Non-Personal	NIL	N/A	N/A	
Hoo Kee Tsang	NPP EAG, ARMEWG	Additional	Faculty of Pain Medicine			Co-chair of the training and assessment committee Faculty of Pain Medicine
Jacqueline McMurtrie	PMEAG	Personal	NIL	N/A	N/A	
Jacqueline McMurtrie	PMEAG	Non-Personal	NIL	N/A	N/A	
Jacqueline McMurtrie	PMEAG	Additional	WRK Orthopedics	Director at WRK Othopedics which is an immediate family member private practice. Have no		Director at WRK Othopedics which is an immediate family members private practice. Have

				involvement with any pharmaceuticals companies.	no involvement with any pharmaceuticals companies.
James Pitayanukul	GRIDEAG	Personal	NIL	N/A	N/A
James Pitayanukul	GRIDEAG	Non-Personal	NIL	N/A	N/A
James Pitayanukul	GRIDEAG	Additional			Treasurer of the National Eczema Society, a charity registered in the UK. A partner in accountancy firm P and Co (Partners) LLP. Adirector of three limited companies: P and Co Services Ltd, Eczema Trading Limited and Good UK Properties Limited.
James Spicer	OHEAG, HPMEWG	Personal	Epsilon Ltd, co-founder	Stock ownership, co-founder	
James Spicer	OHEAG, HPMEWG	Personal	Aethox Therapeutics	Stock ownership, co-founder and director	
James Spicer	OHEAG, HPMEWG	Personal	APOBEC Discovery Ltd	Board Membership - Stock ownership, co-founder	
James Spicer	OHEAG, HPMEWG	Personal	Achilles	Reimbursement to institution for recruitment to clinical trials	
James Spicer	OHEAG, HPMEWG	Personal	Gilead	Reimbursement to institution for recruitment to clinical trials	
James Spicer	OHEAG, HPMEWG	Personal	GlaxoSmithKline	Reimbursement to institution for recruitment to clinical trials	
James Spicer	OHEAG, HPMEWG	Personal	IO Biotech	Reimbursement to institution for recruitment to clinical trials	
James Spicer	OHEAG, HPMEWG	Personal	MSD	Reimbursement to institution for recruitment to clinical trials	
James Spicer	OHEAG, HPMEWG	Personal	Roche	Reimbursement to institution for recruitment to clinical trials	
James Spicer	OHEAG, HPMEWG	Personal	RS Oncology	Reimbursement to institution for recruitment to clinical trials	

James Spicer	OHEAG, HPMEWG	Personal	Starpharma	Reimbursement to institution for recruitment to clinical trials	
James Spicer	OHEAG, HPMEWG	Personal	Avacta Ltd	Stock ownership	
James Spicer	OHEAG, HPMEWG	Non-Personal	BioNTeh	Reimbursement to institution for advisory role	
James Spicer	OHEAG, HPMEWG	Conference s/Scientific Meetings	Sponsor: RS Oncology	Mesothelioma Interest Group	Assistance with attendance at international meetings
James Stones	NPP EAG	Personal	NIL	N/A	N/A
James Stones	NPP EAG	Non-Personal	NIL	N/A	N/A
Jamie Coleman	CHM, PEAG, HPMEWG	Personal	NIL	N/A	N/A International meetings
Jamie Coleman	CHM, PEAG, HPMEWG	Non-Personal	NIL	N/A	N/A
Jamie Fraser	ARMEWG	Personal	NIL	N/A	N/A
Jamie Fraser	ARMEWG	Non-Personal	NIL	N/A	N/A
Janet Brown	OHEAG	Personal	Ipsen	Personal fees for consultancy, advisory boards, travel support to conference	
Janet Brown	OHEAG	Personal	MSD	Personal dees for consultancy, advisory boards	
Janet Brown	OHEAG	Personal	FRESENIUS KABI	Personal fees for Consultancy, advisory boards	
Janet Brown	OHEAG	Personal	Eisai	Personal Fees for Consultancy, advisory boards	
Janet Brown	OHEAG	Non-Personal	NIL	N/A	N/A
Janet Darbyshire	RWD EWG	Personal	NIL	N/A	N/A
Janet Darbyshire	RWD EWG	Non-Personal	NIL	N/A	N/A
John Petrie	CDRRA EAG	Personal	Boehringer-Ingelheim	Endpoint Committee for SYNCRONIZE and LIVERAGE trials (personal fees for	

				Consultancy via University of Glasgow)	
John Petrie	CDRRA EAG	Personal	Merck KGaA	Honorarium for review article commissioned by Diabetes, Obesity and Metabolism for special issue funded by Merck KGAA	
John Petrie	CDRRA EAG	Personal	Sanofi	Attended Sanofi Advisory Board for expert opinion to inform the teplizumab Scottish Medicines Consortium (SMC) HTA submission and pre-symptomatic Type 1 Diabetes clinical management	
John Petrie	CDRRA EAG	Conference s/Scientific Meetings	Sponsor: Sanofi	Registration, accommodation, travel	
John Petrie	CDRRA EAG	Non-Personal	Novo Nordisk	Donation of IMP for investigator-led trial (compassionate due to market supply issues)	
Jon Deeks	HPMEWG	Personal	NIL	N/A	N/A
Jon Deeks	HPMEWG	Non-Personal	NIL	N/A	N/A
Jonathan Lord	MWHEAG	Personal	NIL	N/A	N/A
Jonathan Lord	MWHEAG	Non-Personal	NIL	N/A	N/A
Jonathan Lord	MWHEAG	Additional			Co-chair, abortion taskforce, Royal College of Obstetricians & Gynaecologists (RCOG) Chair, quality committee, British Society of Abortion Care Providers (BSACP) member, FIGO (International Federation of Gynaecology and Obstetrics) committee on safe abortion Member, NICE (National Institute for Health and Care

					Excellence) expert advisor panel member, NICE guideline committee, ectopic pregnancy & miscarriage(NG126) In past 5y, member of NICE committees for abortion care (NG140 & QS199), heavy menstrual bleeding (NG88 & QS47) and fertility (CG156) clinical guidelines & quality standards
Julia Cons	CHM, HPMEWG	Personal	NIL	N/A	N/A
Julia Cons	CHM, HPMEWG	Non-Personal	NIL	N/A	N/A
Julia Cons	CHM, HPMEWG	Additional			Vice chair of the Ministry of Defence Research Ethics Committee.
Julia Cons	CHM, HPMEWG	Additional			Independent Chair of NHS England's Individual Funding Request Panel.
Julia Prague	MWH EAG	Personal	AstraZeneca	Immediate family member has very minor shareholding (as part of mixed investment ISA and pension portfolios)	
Julia Prague	MWH EAG	Personal	Synairgen	Immediate family member has very minor shareholding (as part of mixed investment ISA and pension portfolios)	
Julia Prague	MWH EAG	Personal	Sareum Holdings	Immediate family member has very minor shareholding (as part of mixed investment ISA and pension portfolios)	
Julia Prague	MWH EAG	Personal	GSK	Immediate family member has very minor shareholding (as part of mixed investment ISA and pension portfolios)	

Julia Prague	MWH EAG	Personal	Haleon	Immediate family member has very minor shareholding (as part of mixed investment ISA and pension portfolios)	
Julia Prague	MWH EAG	Non-Personal	NIL	N/A	N/A
Julia Taylor	PMEAG	Personal	NIL	N/A	N/A
Julia Taylor	PMEAG	Non-Personal	NIL	N/A	N/A
Kathryn Johnson	PMEAG	Personal	NIL	N/A	N/A
Kathryn Johnson	PMEAG	Non-Personal	NIL	N/A	N/A
Kenneth Hodson	MWHEAG	Personal	UCB Pharma	Consultancy for UCB Pharma, to advice on methods for postmarketing surveillance	
Kenneth Hodson	MWHEAG	Non-Personal	NIL	N/A	N/A
Kevin Taylor	CPSEAG, HPMEWG	Personal	NIL	N/A	N/A
Kevin Taylor	CPSEAG, HPMEWG	Non-Personal	NIL	N/A	N/A
Kirstie Shearman	CTBVEAG	Personal	NIL	N/A	N/A
Kirstie Shearman	CTBVEAG	Non-Personal	NIL	N/A	N/A
Laura Magee	MWHEAG	Personal	NIL	N/A	N/A
Laura Magee	MWHEAG	Non-Personal	NIL	N/A	N/A
Laurie Tomlinson	MWHEAG	Personal	NIL	N/A	N/A
Laurie Tomlinson	MWHEAG	Non-Personal	NIL	N/A	N/A
Lim Jones	IEAG	Personal	NIL	N/A	N/A
Lim Jones	IEAG	Non-Personal	NIL	N/A	N/A
Linda Pepper	MWHEAG, ARMEWG	Personal	NIL	N/A	N/A

Linda Pepper	MWHEAG, ARMEWG	Non- Personal	NIL	N/A	N/A
Linda Pepper	MWHEAG, ARMEWG	Additional			RCOG MRCOG part 3 exams – lay examiner, NE + NC ICB Secure Data Environment – public member, Newcastle NHS Trust – public governor
Lisa Brownell	NPPEAG	Personal	NIL	N/A	N/A
Lisa Brownell	NPPEAG	Non- Personal	NIL	N/A	N/A
Louis Grandjean	IEAG	Personal	Shionogi	Grant (£20k) research into drug resistance to Cefiderocol	
Louis Grandjean	IEAG	Personal	Pfizer	Consultancy and Grant (£50k for research into drug resistance to CZA)	
Louis Grandjean	IEAG	Personal	Advanz	Grant (£20k) research into drug resistance	
Louis Grandjean	IEAG	Personal	Mundipharma	Research into efficacy of the drug	
Louis Grandjean	IEAG	Conference s/Scientific Meetings	Sponsor: Pfizer	£10k sponsorship of the event that I co-organised	
Louis Grandjean	IEAG	Non- Personal	NIL	N/A	N/A
Louise Massey	MWHEAG	Personal	NIL	N/A	N/A
Louise Massey	MWHEAG	Non- Personal	NIL	N/A	N/A
Louise Picton	ARMEWG	Personal	NIL	N/A	N/A
Louise Picton	ARMEWG	Non- Personal	NIL	N/A	N/A
Louise Picton	ARMEWG	Additional	Reckitt	Immediate family member works for Reckitt in an IT role and has shares in the company	
Luigi (Gino) Martini	CPSEAG	Personal	GSK	Shares with GSK and pension	

Luigi (Gino) Martini	CPSEAG	Personal	LUPA MEDICAL	Fees from GSK, MSD, Becton Dickinson, Pinsent Masons, Knobbe Martin, GPHC	Private Consultancy owned by member
Luigi (Gino) Martini	CPSEAG	Personal	Colltech Labs	Minority Shareholding < 5% and unpaid	
Luigi (Gino) Martini	CPSEAG	Personal	Biotherapy Services Ltd	Minority Shareholding < 5% and unpaid	
Luigi (Gino) Martini	CPSEAG	Personal	Altabiome Therapeutics Limited	Minority Shareholding < 5% and unpaid	Company Dissolved September 2025 - no longer associated with the company
Luigi (Gino) Martini	CPSEAG	Personal	Kiffik	Minority Shareholding and unpaid	
Luigi (Gino) Martini	CPSEAG	Personal	Lakes BioScience Ltd	Unpaid but share holder	Director
Luigi (Gino) Martini	CPSEAG	Personal	Nash Therapeutics Ltd	Unpaid but share holder	
Luigi (Gino) Martini	CPSEAG	Personal	BIOSIMAX Ltf	Unpaid but share holder	Director
Luigi (Gino) Martini	CPSEAG	Personal	Newavx Ltd	Unpaid but share holder	
Luigi (Gino) Martini	CPSEAG	Personal	One Thousand Trade Group	Minority shareholder and unpaid	
Luigi (Gino) Martini	CPSEAG	Additional		Immediate family member has shares in GSK and SB as well as pension	Immediate family member was a former SB and GSK manager but has now retrained as a Teacher in Science Daughter is now a fully qualified Pharmacist and works at the Barts Trust across London
Ly-Mee Yu	HPMEWG	Personal	NIL	N/A	N/A
Ly-Mee Yu	HPMEWG	Non-Personal	NIL	N/A	N/A
Majella Lane	CPSEAG	Personal	NIL	N/A	N/A
Majella Lane	CPSEAG	Non-Personal	NIL	N/A	N/A
Malcolm Oswald	PEAG	Personal	NIL	N/A	N/A

Malcolm Oswald	PEAG	Non-Personal	NIL	N/A	N/A
Marc Turner	CHM, CTBVEAG, HPMEWG	Personal	NIL	N/A	N/A
Marc Turner	CHM, CTBVEAG, HPMEWG	Non-Personal	Novo Nordisk	SNBTS worked with Company on preclinical development of a pluripotent stem cell derived Islet product	
Mark Evans	CDRRA EAG	Personal	Abbott Diabetes Care	Speakers fees, Clinical triallist on a multicentre study sponsored by Abbott Diabetes Care	
Mark Evans	CDRRA EAG	Personal	Eli Lilly	Speakers Fees	
Mark Evans	CDRRA EAG	Personal	Pila Pharma	Advisory board Planned clinical triallist	
Mark Evans	CDRRA EAG	Personal	Zucara	(Advisory Board	
Mark Evans	CDRRA EAG	Personal	Sanofi	Advisory boards Speakers fees	
Mark Evans	CDRRA EAG	Personal	vTV pharma	Advisory Board	
Mark Evans	CDRRA EAG	Conference s/Scientific Meetings	Eli Lilly	Travel expenses and speaker's fee as above	
Mark Evans	CDRRA EAG	Conference s/Scientific Meetings	Sanofi	Travel expenses and registration	
Mark Evans	CDRRA EAG	Non-Personal	Abbott Diabetes Care	Clinical triallist	
Mark Evans	CDRRA EAG	Non-Personal	Lexicon	Planned clinical triallist	
Mark Evans	CDRRA EAG	Non-Personal	NovoNordisk	Sponsored PhD studentship as supervisor	
Martin English	PMEAG	Personal	NIL	N/A	N/A
Martin English	PMEAG	Non-Personal	NIL	N/A	N/A
Martin Kaiser	OHEAG	Personal	GlaxoSmithKline	Consultancy	
Martin Kaiser	OHEAG	Personal	Pfizer	Consultancy	

Martin Kaiser	OHEAG	Personal	Takeda	Consultancy	
Martin Kaiser	OHEAG	Personal	Johnson and Johnson	Speaker fees	
Martin Kaiser	OHEAG	Personal	Abbvie	Consultancy	
Martin Kaiser	OHEAG	Personal	Kite/Arcellx	Consultancy	
Martin Kaiser	OHEAG	Personal	Roche	consultancy	
Martin Kaiser	OHEAG	Personal	Regeneron		
Martin Kaiser	OHEAG	Non-Personal	Regeneron	Research grant	
Martin Kaiser	OHEAG	Non-Personal	Johnson and Johnson	Research grant	
Martin Kaiser	OHEAG	Non-Personal	BMS	Research grant	
Martin Wilson	CHM	Personal	NIL	N/A	N/A
Martin Wilson	CHM	Non-Personal	NIL	N/A	N/A
Matthias Schmid	IEAG	Personal	NIL	N/A	N/A
Matthias Schmid	IEAG	Non-Personal	NIL	N/A	N/A
Merryn Voysey	CTBVEAG	Personal	LightHearted Health AI Limited	Consultancy	
Merryn Voysey	CTBVEAG	Personal	Inventprise	Consultancy	
Merryn Voysey	CTBVEAG	Non-Personal	NIL	N/A	N/A
Michael Ardern-Jones	GRIDEAG	Personal	Sanofi-Genzyme	Consultancy, Advisory board fees, Conference attendance, Speaker fees	
Michael Ardern-Jones	GRIDEAG	Personal	Leo Pharma	Consultancy, Advisory board fees, Conference attendance, Speaker fees	
Michael Ardern-Jones	GRIDEAG	Personal	AbbVie	Consultancy, Advisory board fees, Conference attendance, Speaker fees	
Michael Ardern-Jones	GRIDEAG	Personal	Pfizer	Consultancy, Advisory board fees, Conference attendance, Speaker fees	

Michael Ardern-Jones	GRIDEAG	Personal	Lilly	Consultancy, Advisory board fees
Michael Ardern-Jones	GRIDEAG	Personal	J&J (including Janssen)	Consultancy, Advisory board fees, Conference attendance, Speaker fees
Michael Ardern-Jones	GRIDEAG	Personal	Almirall	Consultancy, Advisory board fees, Conference attendance, Speaker fees
Michael Ardern-Jones	GRIDEAG	Personal	Galderma	Consultancy, Advisory board fees, Conference attendance, Speaker fees
Michael Ardern-Jones	GRIDEAG	Personal	Novartis	Consultancy, Advisory board fees, Conference attendance, Speaker fees
Michael Ardern-Jones	GRIDEAG	Personal	Regeneron	Consultancy, Advisory board fees, Conference attendance, Speaker fees
Michael Ardern-Jones	GRIDEAG	Personal	Incyte	Consultancy, Advisory board fees, Conference attendance, Speaker fees
Michael Ardern-Jones	GRIDEAG	Personal	PPD	Consultancy, Advisory board fees, Conference attendance, Speaker fees
Michael Ardern-Jones	GRIDEAG	Personal	Mission	Consultancy, Advisory board fees, Conference attendance, Speaker fees
Michael Ardern-Jones	GRIDEAG	Conference s/Scientific Meetings	Sanofi-Genzyme	Consultancy, Advisory board fees, Conference attendance, Speaker fees
Michael Ardern-Jones	GRIDEAG	Conference s/Scientific Meetings	Leo Pharma	Consultancy, Advisory board fees, Conference attendance, Speaker fees
Michael Ardern-Jones	GRIDEAG	Conference s/Scientific Meetings	AbbVie	Consultancy, Advisory board fees, Conference attendance, Speaker fees

Michael Ardern-Jones	GRIDEAG	Conference s/Scientific Meetings	Pfizer	Consultancy, Advisory board fees, Conference attendance, Speaker fees
Michael Ardern-Jones	GRIDEAG	Conference s/Scientific Meetings	Lilly	Consultancy, Advisory board fees
Michael Ardern-Jones	GRIDEAG	Conference s/Scientific Meetings	J&J (including Janssen)	Consultancy, Advisory board fees, Conference attendance, Speaker fees
Michael Ardern-Jones	GRIDEAG	Conference s/Scientific Meetings	Almirall	Consultancy, Advisory board fees, Conference attendance, Speaker fees
Michael Ardern-Jones	GRIDEAG	Conference s/Scientific Meetings	Galderma	Consultancy, Advisory board fees, Conference attendance, Speaker fees
Michael Ardern-Jones	GRIDEAG	Conference s/Scientific Meetings	Novartis	Consultancy, Advisory board fees, Conference attendance, Speaker fees
Michael Ardern-Jones	GRIDEAG	Conference s/Scientific Meetings	Regeneron	consultancy, Advisory board fees, Conference attendance, Speaker fees
Michael Ardern-Jones	GRIDEAG	Conference s/Scientific Meetings	Incyte	Consultancy, Advisory board fees, Conference attendance, Speaker fees
Michael Ardern-Jones	GRIDEAG	Conference s/Scientific Meetings	PPD	Consultancy, Advisory board fees, Conference attendance, Speaker fees
Michael Ardern-Jones	GRIDEAG	Conference s/Scientific Meetings	Mission	Consultancy, Advisory board fees, Conference attendance, Speaker fees
Michael Ardern-Jones	GRIDEAG	Non-Personal	J&J (including Janssen)	Grant funding
Michael Ardern-Jones	GRIDEAG	Non-Personal	Mission therapeutics	Consultancy, Advisory board fees, Conference attendance, Speaker fees

Michael Ardern-Jones	GRIDEAG	Non-Personal	Ducentis	UoS collaboration research	
Michael Ardern-Jones	GRIDEAG	Non-Personal	Almirall	UHS Commercial clinical trial	
Michael Ardern-Jones	GRIDEAG	Non-Personal	Abbvie	UHS Commercial clinical trial	
Michael Ardern-Jones	GRIDEAG	Non-Personal	Leo Pharma	UHS Commercial clinical trial	
Michael Ardern-Jones	GRIDEAG	Non-Personal	Leo Pharma	UHS Commercial clinical trial	
Michael Ardern-Jones	GRIDEAG	Non-Personal	Amgen	UHS Commercial clinical trial	
Michael Ardern-Jones	GRIDEAG	Non-Personal	Sanofi	UoS collaboration research, UHS Commercial Trial	
Michael Ardern-Jones	GRIDEAG	Non-Personal	Pfizer	UoS collaboration research	
Michael Ardern-Jones	GRIDEAG	Additional			Biotechnology and Biological Sciences Research Council iCASE industrial studentships have been funded at the institution with Unilever. Supervised PhDs. Unilever is a consumer goods manufacturer, with an interest in skin science. Member has collaborated with Emblation (unpaid) and have received small donations towards research programme.
Michael Brown	IEAG	Personal	NIL	N/A	N/A
Michael Brown	IEAG	Non-Personal	GSK	The Infection Division at UCLH for which the role of DCD is held, received funds for recruitment of patients into the LUNAR SARS-CoV-2 variant monitoring study. The role of the local PI.	

Michael Brown	IEAG	Non-Personal	AstraZeneca	The Infection Division at UCLH for which the role of DCD is held, received funds for recruitment of patients into the TILIA study of this anti-IL33 drug. The role of the local PI.	
Michael Brown	IEAG	Non-Personal	Staatens Serum Institute (sponsor)	The Infection Division at UCLH for which the role of DCD is held, received funds for recruitment of patients into the inpatient and outpatient remdesivir trials. Local PI for three trials and UK CI for one trial	
Michael Brown	IEAG	Non-Personal	Astra Zeneca	The Infection Division at UCLH for which the role of DCD is held, received funds for recruitment of patients into the inpatient and outpatient remdesivir trials. Local PI for three trials and UK CI for one trial	
Michael Steiner	CDRRA EAG	Personal	NIL	N/A	N/A
Michael Steiner	CDRRA EAG	Non-Personal	NIL	N/A	N/A
Morris Zwi	ARMEWG	Personal	NIL	N/A	N/A
Morris Zwi	ARMEWG	Non-Personal	NIL	N/A	N/A
Munir Pirmohamed	CHM, HPMEWG, RWD EWG	Personal	NIL	N/A	N/A
Munir Pirmohamed	CHM, HPMEWG, RWD EWG	Conference s/Scientific Meetings	NIL	N/A	N/A
Munir Pirmohamed	CHM, HPMEWG, RWD EWG	Non-Personal	AstraZeneca	Research grant to University of Liverpool (UoL), University of Manchester (UoM), University of Glasgow (UoG) and Queen Mary University London (QMUL) to	

				support clinical fellowships jointly with UK Medical Research Council (MRC)
Munir Pirmohamed	CHM, HPMEWG, RWD EWG	Non-Personal	Eli Lilly	Research grant to Universities of Liverpool (UoL) and Manchester (UoM) to support clinical training fellowships jointly with UK Medical Research Council (MRC)
Munir Pirmohamed	CHM, HPMEWG, RWD EWG	Non-Personal	Novartis	Research grant to UoL and UoM to support clinical training fellowships jointly with MRC
Munir Pirmohamed	CHM, HPMEWG, RWD EWG	Non-Personal	Roche	Research grant to UoL and UoM to support clinical training fellowships jointly with MRC
Munir Pirmohamed	CHM, HPMEWG, RWD EWG	Non-Personal	UCB Pharma	Research grant to UoL and UoM to support clinical training fellowships jointly with MRC
Munir Pirmohamed	CHM, HPMEWG, RWD EWG	Non-Personal	GSK	Research grant to University of Liverpool (UoL), University of Manchester (UoM), University of Glasgow (UoG) and Queen Mary University London (QMUL) to support clinical fellowships jointly with UK Medical Research Council (MRC)
Munir Pirmohamed	CHM, HPMEWG, RWD EWG	Non-Personal	Optum	Research grant to University of Liverpool (UoL), University of Manchester (UoM), University of Glasgow (UoG) and Queen Mary University London (QMUL) to support clinical fellowships jointly with UK Medical Research Council (MRC)
Munir Pirmohamed	CHM, HPMEWG, RWD EWG	Non-Personal	Hammersmith Medicines Research	Research grant to University of Liverpool (UoL), University of Manchester (UoM), University of

			Glasgow (UoG) and Queen Mary University London (QMUL) to support clinical fellowships jointly with UK Medical Research Council (MRC)
Munir Pirmohamed	CHM, HPMEWG, RWD EWG	Additional	Part of the IMI Consortium called ARDAT (https://ardat.org/). This is partnership funding for research through the EU Commission, with academic partners receiving funding via the EU (to the University of Liverpool), while Industry partners provide their expertise as an in-kind contribution. The companies involved in the IMI programme are: Pfizer/Bayer/Janssen Pharmaceutica NV /Lonza AG /Novartis /Novo Nordisk /Sanofi-Aventis /Spark Therapeutics, Inc /Takeda Pharmaceuticals International AG /Viscofan SA /Astellas Pharma Europe BV /Roche Declared as NP/NS when any of their products are discussed.
Munir Pirmohamed	CHM, HPMEWG, RWD EWG	Additional	Chair of the Prix Galien UK prize awarding committee from September 2023.
Munir Pirmohamed	CHM, HPMEWG, RWD EWG	Additional	Medical Trustee for the British Heart Foundation, and member of the governing council of the Medical Research Council. Advised the Qatar Precision

					Health Initiative and the Bosch Health Foundation on research related to personalised medicine and pharmacogenomics.
Nashat Qamar	PEAG	Personal	NIL	N/A	N/A
Nashat Qamar	PEAG	Non-Personal	NIL	N/A	N/A
Nicol Ferrier	ARMEWG	Personal	NIL	N/A	N/A
Nicol Ferrier	ARMEWG	Non-Personal	NIL	N/A	N/A
Nidhi Sofat	GRIDEAG	Personal	NIL	N/A	N/A
Nidhi Sofat	GRIDEAG	Non-Personal	NIL	N/A	N/A
Nigel Stallard	HPMEWG	Personal	NIL	N/A	N/A
Nigel Stallard	HPMEWG	Non-Personal	Novartis	PhD student funding	
Nigel Stallard	HPMEWG	Non-Personal	Janssen	PhD student funding	
Nigel Stallard	HPMEWG	Non-Personal	Boehringer Ingelheim	PhD student funding	
Nigel Westwood	CDRRA EAG	Personal	NIL	N/A	N/A
Nigel Westwood	CDRRA EAG	Non-Personal	NIL	N/A	N/A
Nigel Westwood	CDRRA EAG	Additional			Lay member on NICE Technology Appraisal Committee B since March 2016 and paid an honorarium and expenses for each meeting attended.
Nikoletta Fotaki	CPSEAG	Personal	NIL	N/A	N/A
Nikoletta Fotaki	CPSEAG	Non-Personal	NIL	N/A	N/A
Nikoletta Fotaki	CPSEAG	Additional	Dr Fotaki BioPharm Consulting		Director of Dr Fotaki BioPharm Consulting (The Registrar of Companies for England and

Wales- Company number: 13238377).					
Patricia McGettigan	PEAG	Personal	NIL	N/A	N/A
Patricia McGettigan	PEAG	Non-Personal	NIL	N/A	N/A
Patricia McGettigan	PEAG	Additional			Independent Expert member of the European Medicines Agency Pharmacovigilance Risk Assessment Committee. Immediate family member is a Director of Aer Beatha Ltd. The company markets cardboard spacers for use with metered dose inhalers for asthma / COPD.
Patrick Holmes	CDRRA EAG	Personal	Daiichi-Sankyo	Advisory board honararium	
Patrick Holmes	CDRRA EAG	Personal	Grunenthal	Expenses and support for Clinical Paper Development and Presentation on Diabetic Peripheral neuropath	
Patrick Holmes	CDRRA EAG	Personal	Eli Lilly	Speaker Fees	
Patrick Holmes	CDRRA EAG	Conference s/Scientific Meetings	DoH & Eli Lilly	Expenses and honoraria	N/A
Patrick Holmes	CDRRA EAG	Non-Personal	NIL	N/A	N/A
Paul Dargan	CHM	Personal	NIL	N/A	N/A
Paul Dargan	CHM	Non-Personal	NIL	N/A	N/A
Paul Dargan	CHM	Additional			Chair of the Royal College of Emergency Medicine and National Poisons Information Service Antidote Guidelines Group which oversees advice to hospitals in England for the

stocking of antidotes; Chaired this group since 2008. This group provides advice on the amount of antidote to be stocked by hospitals and the time-frame that the antidotes should be available. The advice is based on the published literature and there is no liaison with the pharmaceutical industry in relation to the guidance published by this group.

Paul Dargan CHM Additional
EAPCCT: President of the European Association of Poisons Control Centres and Clinical Toxicologists (EAPCCT: <http://www.eapcct.org/>) from May 2024 to May 2026. The EAPCCT is the European Clinical Toxicology Society and its main role is to organise the annual European Toxicology Conference “with the specific goal of advancing knowledge and understanding of the diagnosis and treatment of all forms of poisoning”.

Paul Dargan CHM Additional
Expert adviser on clinical toxicology to the World Health Organisation- this predominantly involved advising on issues in relation to lead and mercury poisoning. Also contributed to WHO

					monographs and guidelines for lead and mercury poisoning.
Paul Dargan	CHM	Additional			Associate Editor for Clinical Toxicology and sit on the International Editorial Board of the British Journal of Clinical Pharmacology.
Paul Dargan	CHM	Additional			Immediate family member is a practising NHS GP.
Perminder Tony Singh Dhillon	OHEAG	Personal	Mount Alvernia PET CT Limited	Shares	
Perminder Tony Singh Dhillon	OHEAG	Non-Personal	Nil	N/A	N/A
Peter Buckle	HPMEWG	Personal	NIL	N/A	N/A
Peter Buckle	HPMEWG	Non-Personal	NIL	N/A	N/A
Peter Hall	RWD EWG	Personal	NIL	N/A	N/A
Peter Hall	RWD EWG	Non-Personal	Lilly	Consultancy	2020 - ongoing
Peter Hall	RWD EWG	Non-Personal	Menarini	Consultancy	18/02/2025
Peter Hall	RWD EWG	Non-Personal	Okin	Research funding	2025-ongoing
Peter Hall	RWD EWG	Non-Personal	MSD	Consultancy	2022-ongoing
Peter Hall	RWD EWG	Non-Personal	Roche	Consultancy	2021-2025
Peter Hall	RWD EWG	Non-Personal	SeaGen	Consultancy	2021-2025
Peter Hall	RWD EWG	Non-Personal	IQVIA	Consultancy	2025-2026
Peter Pratt	ARMEWG	Personal	NIL	N/A	N/A
Peter Pratt	ARMEWG	Non-Personal	NIL	N/A	N/A
Philip Hannaford	MWHEAG	Personal	NIL	N/A	N/A

Philip Hannaford	MWHEAG	Non-Personal	NIL	N/A	N/A
Poulam M Patel	CHM, OHEAG, HPMEWG	Personal	NIL	N/A	N/A
Poulam M Patel	CHM, OHEAG, HPMEWG	Non-Personal	Scancell	CI & local PI for company sponsored trial	Yes
Poulam M Patel	CHM, OHEAG, HPMEWG	Non-Personal	Merck	Local PI for company sponsored trial	Yes
Rajeev Shah	PEAG	Personal	NIL	N/A	
Rajeev Shah	PEAG	Conference s/Scientific Meetings	NICE Health Technology Away Day	Travel and accommodation expenses reimbursed	
Rajeev Shah	PEAG	Conference s/Scientific Meetings	HLTH Conference, Amsterdam	Travel allowance received	
Rajeev Shah	PEAG	Non-Personal	NIHR	I4i committee MedTech funding member (honorary)	
Rajeev Shah	PEAG	Non-Personal	NEJM	Advisory Council member (honorary)	
Ravishankar Sargur	GRIDEAG	Personal	NIL	N/A	N/A
Ravishankar Sargur	GRIDEAG	Conference s/Scientific Meetings	CSL Behring -10th HAEExpert Face-to-Face Meeting	Travel, accommodation, registration information, subsistence, CSL Behring C	
Ravishankar Sargur	GRIDEAG	Non-Personal	NIL	N/A	N/A
Rebecca Kristeleit	OHEAG	Non-Personal	Various	Academic and Commercial Clinical Trial Programme with payments for trial work given to Institution	
Rebecca Kristeleit	OHEAG	Personal	Eisai	Consultancy	
Rebecca Kristeleit	OHEAG	Personal	GSK	Consultancy	
Rebecca Kristeleit	OHEAG	Personal	Roche	Consultancy	

Rebecca Kristeleit	OHEAG	Personal	Clovis	Consultancy and grants		
Rebecca Kristeleit	OHEAG	Personal	AstraZeneca	Consultancy		
Rebecca Kristeleit	OHEAG	Personal	Beigene	Pending grant		
Rebecca Kristeleit	OHEAG	Personal	Pharmamar	Consultancy and pending grant		
Rebecca Kristeleit	OHEAG	Personal	Amphista	Consultancy		
Rebecca Kristeleit	OHEAG	Personal	Basilea	Consultancy		
Reecha Sofat	PEAG	Personal	Aegon	Investment	Yes	Investment portfolio managed by an advisor
Reecha Sofat	PEAG	Non-Personal	NIL	N/A	N/A	
Reecha Sofat	PEAG	Additional				Chair of the Professional Record Standards Body, NIHR Research Professorship, funded by the NIHR, Associate Director at the British Heart Foundation Data Science Centre
Rhian Thomas-Turner	PMEAG	Personal	NIL	N/A	N/A	
Rhian Thomas-Turner	PMEAG	Conference s/Scientific Meetings	AstraZeneca, Sanofi, C4C, Novartis, Efpia, UCB	Sponsorship of conference - no personal benefit		
Rhian Thomas-Turner	PMEAG	Non-Personal	Sanofi/Protect Bio	Employing organisation participating in study		
Rhian Thomas-Turner	PMEAG	Non-Personal	Astell	Team participation in Skipper (gilteritinib) and nephrology study CKD study		
Rhian Thomas-Turner	PMEAG	Non-Personal	Moderna	Employing organisation participating in study		

Rhian Thomas-Turner	PMEAG	Non-Personal	Epygenix Therapeutics	Employing organisation participating in study	
Rhian Thomas-Turner	PMEAG	Non-Personal	Argen X	Employing organisation participating in study	
Rhian Thomas-Turner	PMEAG	Non-Personal	Pierre Fabre	Employing organisation participating in study	
Rhian Thomas-Turner	PMEAG	Non-Personal	Vertex Pharma	Employing organisation participating in study	
Rhian Thomas-Turner	PMEAG	Non-Personal	Abbott	Employing organisation participating in study	
Rhian Thomas-Turner	PMEAG	Non-Personal	BMS	Employing organisation participating in study	
Rhian Thomas-Turner	PMEAG	Non-Personal	Ipsen Pharma	Employing organisation participating in study	
Rhian Thomas-Turner	PMEAG	Non-Personal	Sobi	Employing organisation participating in study	
Rhian Thomas-Turner	PMEAG	Non-Personal	Kyowa Kirin Pharmaceutical Development Ltd	Employing organisation participating in study	
Rhian Thomas-Turner	PMEAG	Non-Personal	MSD	Employing organisation participating in study	
Rhian Thomas-Turner	PMEAG	Non-Personal	X4 Pharmaceuticals	Employing organisation participating in study	
Rhian Thomas-Turner	PMEAG	Non-Personal	Nova Laboratories Ltd	Employing organisation participating in study	
Rhian Thomas-Turner	PMEAG	Additional			Organisation has received funding from the ABPI via the VPAG scheme which supports commercial trial infrastructure.
Richard Fitzgerald	CHM, PEAG	Additional			Director of NIHR Liverpool Clinical Research Facility, a part of University Hospitals of Liverpool NHS Group, which conducts academic and commercially funded research.

Richard Fitzgerald	CHM, PEAG	Personal	NIL	N/A	N/A
Richard Fitzgerald	CHM, PEAG	Non-Personal	NIL	N/A	N/A
Richard Gilson	IEAG	Personal	NIL	N/A	N/A
Richard Gilson	IEAG	Non-Personal	Gilead Sciences	Department is a collaborating site in clinical trials sponsored by Gilead Sciences, who have provided research funds to the department (received by UCL and by Central and North West London NHS Foundation Trust) in clinical trials sponsored by Gilead Sciences, who have provided research funds to the department (received by UCL and by Central and North West London NHS Foundation Trust)	
Richard Gilson	IEAG	Non-Personal	GSK	Department is a collaborating site in clinical trials sponsored by GSK, who have provided research funds to the department (received by UCL and by Central and North West London NHS Foundation Trust)	
Richard Gilson	IEAG	Non-Personal	Merck	Department is a collaborating site in clinical trials sponsored by Merck, who have provided research funds to the department (received by UCL and by Central and North West London NHS Foundation Trust)	
Richard Gilson	IEAG	Non-Personal	Pfizer	Department is a collaborating site in clinical trials sponsored by Pfizer, who have provided research	

				funds to the department (received by UCL and by Central and North West London NHS Foundation Trust)	
Richard Gilson	IEAG	Non-Personal	ViiV	Department is a collaborating site in clinical trials sponsored by ViiV, who have provided research funds to the department (received by UCL and by Central and North West London NHS Foundation Trust)	
Richard Gilson	IEAG	Non-Personal	Procure Women Health Limited	Consultancy as Senior Scientific Advisor to Procure through a contract with UCL Consultants. All proceeds received by the UCL Institute for Global Health.	
Richard Nicholas	NPPEAG	Personal	NIL	N/A	N/A
Richard Nicholas	NPPEAG	Non-Personal	NIL	N/A	N/A
Richard Nicholas	NPPEAG	Additional			Met with Novartis (unpaid) in 2025 regarding updating a study on MAICs in progressive MS further to a paper done with them in 2020: Samjoo IA, Worthington E, Haltner A, Cameron C, Nicholas R, Rouyrre N, Dahlke F, Adlard N. Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple sclerosis. Current Medical Research & Opinion 27 Mar 2020; 10.1080/03007995.2020.17479

99.
Samjoo IA, Worthington E, Haltner A, Groot M, Nicholas R, Cameron C, Rouyrre N, Dahlke F, Adlard N. The Importance of Considering Differences in Study and Patient Characteristics Before Undertaking Indirect Treatment Comparisons: A Case Study of Siponimod for Secondary Progressive Multiple Sclerosis. Current Medical Research & Opinion 27 Mar 2020: 10.1080/03007995.2020.1747998.

Robert Andrews	HPMEWG	Personal	NIL	N/A	N/A
Robert Andrews	HPMEWG	Non-Personal	NIL	N/A	N/A
Robert Brown	HPMEWG	Personal	NIL	N/A	N/A
Robert Brown	HPMEWG	Non-Personal	NIL	N/A	N/A
Robert Lowe	CPSEAG, HPMEWG	Personal	Baxter Healthcare	Personal non-specific interest – consultancy on branding and product usage	
Robert Lowe	CPSEAG, HPMEWG	Non-Personal	NIL	N/A	N/A
Robin Thorpe	CTBV, HPMEWG	Personal	NIL	N/A	N/A
Robin Thorpe	CTBV, HPMEWG	Non-Personal	NIL	N/A	N/A
Rona Smith	CDRRA EAG	Personal	AstraZeneca	Consultancy and honoraria	
Rona Smith	CDRRA EAG	Non-Personal	GlaxoSmithKline	Clinical Study Grant	
Rui Providencia	CHM	Personal	NIL	N/A	N/A
Rui Providencia	CHM	Non-Personal	NIL	N/A	N/A

Rupert Payne	PEAG	Personal	NIL	N/A	N/A
Rupert Payne	PEAG	Non-Personal	NIL	N/A	N/A
Rupert Payne	PEAG	Additional	Wiley publishers - the journal Prescriber		Paid role (until Jan 2025) as Consultant Editor for journal Prescriber (Wiley publishing), which carried pharmaceutical company advertising (editorial role was independent of advertising/marketing)
Ruth Paulin	CPSEAG	Personal	NIL	N/A	N/A
Ruth Paulin	CPSEAG	Non-Personal	NIL	N/A	N/A
Sandosh Padmanabhan	CHM, CDRRA EAG, HPMEWG	Personal	Kvatchii Limited	Founder shares	
Sandosh Padmanabhan	CHM, CDRRA EAG, HPMEWG	Personal	Lighthearted.ai	Consultancy	
Sandosh Padmanabhan	CHM, CDRRA EAG, HPMEWG	Non-Personal	NIL	N/A	N/A
Sarah Meredith	RWD EWG	Non-Personal	NIL	N/A	N/A
Sarah Meredith	RWD EWG	Personal	NIL	N/A	N/A
Serena Nik-Zainal	HPMEWG	Personal	Otoimmune	Shares	
Serena Nik-Zainal	HPMEWG	Non-Personal	NIL	N/A	N/A
Serena Nik-Zainal	HPMEWG	Additional			Patent filings on cancer genomics / mutational signatures. Not relevant to work performed on committee.
Shahida Din	GRIDEAG	Personal	Abbvie IBD Distinction Roadshow Edinburgh	Speaker fees	
Shahida Din	GRIDEAG	Personal	Takeda Leeds IBD Exchange	Travel, accommodation, speaker fees	

Shahida Din	GRIDEAG	Personal	Dr FALK Glasgow	Travel, accommodation, speaker fees
Shahida Din	GRIDEAG	Personal	Lilly Gut Feelings London	Travel, accommodation, speaker fees
Shahida Din	GRIDEAG	Personal	IBD Matters London Johnson & Johnson	Travel, speaker fees
Shahida Din	GRIDEAG	Conference s/Scientific Meetings	Takeda - Takeda Insights Beyond Data Meeting	Travel, accommodation, Symposium registration fees
Shahida Din	GRIDEAG	Conference s/Scientific Meetings	Lilly - European Crohn's & Colitis Annual Meeting	Flights, accommodation, Symposium Registration Fees
Shahida Din	GRIDEAG	Conference s/Scientific Meetings	Abbvie - Digestives Diseases Week Annual Meeting	
Shahida Din	GRIDEAG	Conference s/Scientific Meetings	Dr Falk - Dr FALK Immunology Symposium Oxford	Registration, travel, accommodation support
Shahida Din	GRIDEAG	Non- Personal	Edinburgh & Lothian Health Foundations Award	Research funding
Shahida Din	GRIDEAG	Non- Personal	Pathological Society of Great Britain & Northern Ireland	Research funding
Shahida Din	GRIDEAG	Non- Personal	Helmsley Charitable Trust: Gut Cell Atlas Normal & Crohn's Disease	Research funding
Shahida Din	GRIDEAG	Non- Personal	Helmsley Charitable trust: Combination	Research funding

			therapy with BIOlogics and Partial enteral nutrition In adults with active ileocolonic Crohn's disease. The BIOPIC Study	
Shahida Din	GRIDEAG	Non- Personal	Helmsley Charitable Trust: An open label pilot study of the CD- TREAT (Crohn's Disease Treatment-with- EATing) diet as a novel therapy for active luminal Crohn's disease	Research funding
Shahida Din	GRIDEAG	Additional		Leadership Roles 1. British Society of Gastroenterology 2019 to date Inflammatory Bowel Disease Section Committee Member 2. Chair of the British Society of Gastroenterology Inflammatory Bowel Disease Committee June 2024 to 2027 3. Royal College of Physicians of Edinburgh January 2020 to January 2025 Gastroenterology Specialty Advisor Additional Information to cover period 1 January 2025 to 31 December 2025

Collaborator for Clinical Trial
MARVEL Mitochondrial Anti-oxidant therapy to Resolve Inflammation in Ulcerative Colitis (MARVEL): A randomised placebo-controlled trial on oral MitoQ in moderate to severe active UC.
Funder John Moulton Foundation Sponsor NHS Lothian/University of Edinburgh

Principal (or Sub) Investigator for Clinical Trial
Start Date August 2019 to ongoing

Current Trials
Role Sub-PI
Identifying the role of food additives in Crohn's Disease using a randomized controlled trial of a low-emulsifier diet: the ADDapt trial Funder Helmsley Charitable Trust Sponsor King's College London Start Date November 2023 – ongoing

Role Sub-PI
Optimisation before Crohn's surgery using Exclusive Enteral Nutrition- OCEAN study Funder NIHR -HTA Sponsor University of Birmingham Start Date August 2024 – ongoing

Shirley Price	PMEAG, HPMEWG	Personal	NIL	N/A	N/A
Shirley Price	PMEAG, HPMEWG	Non-Personal	GSK	Annual donation to the British Toxicology Society of which a Trustee for support of education and training activities. The BTS is a charity and its Charity Registration No: 286197	Hold an Honorary Fellowships from the British Toxicology Society and the UK Health Security Agency.
Shirley Price	PMEAG, HPMEWG	Non-Personal	AstraZeneca	Annual donation to the British Toxicology Society of which a Trustee for support of education and training activities. The BTS is a charity and its Charity Registration No: 286197	Hold an Honorary Fellowships from the British Toxicology Society and the UK Health Security Agency.
Shirley Price	PMEAG, HPMEWG	Non-Personal	Apconix	Donation to the British Toxicology Society of which a Trustee, for general support of the 2024 Annual Congress. The BTS is a charity and its Charity Registration No: 286197	Hold an Honorary Fellowships from the British Toxicology Society and the UK Health Security Agency.
Shuaib Nasser	CDRRA EAG	Personal	Galderma	Advisory Board	
Shuaib Nasser	CDRRA EAG	Personal	ALK	Advisory Board	
Shuaib Nasser	CDRRA EAG	Conference s/Scientific Meetings	Chiesi	Conference registration and cost of hotel	British Thoracic Society
Shuaib Nasser	CDRRA EAG	Non-Personal	NIL	N/A	N/A
Simon Drysdale	PMEAG	Personal	NIL	N/A	N/A
Simon Drysdale	PMEAG	Non-Personal	MSD	Investigator Initiated research grant (all funds paid to institution)	
Simon Drysdale	PMEAG	Non-Personal	Pfizer	Investigator Initiated research grant (all funds paid to institution)	
Simon Drysdale	PMEAG	Non-Personal	Merck	Local PI or national CI for multiple research studies for multiple pharmaceutical companies	

Simon Drysdale	PMEAG	Non-Personal	AstraZeneca	Local PI or national CI for multiple research studies for multiple pharmaceutical companies	
Simon Drysdale	PMEAG	Non-Personal	ILiAD	Local PI or national CI for multiple research studies for multiple pharmaceutical companies	
Simon Drysdale	PMEAG	Non-Personal	Moderna	Local PI or national CI for multiple research studies for multiple pharmaceutical companies	
Simon Drysdale	PMEAG	Non-Personal	Valneva	Local PI or national CI for multiple research studies for multiple pharmaceutical companies	
Simon Drysdale	PMEAG	Non-Personal	Sanofi Pasteur	Local PI or national CI for multiple research studies for multiple pharmaceutical companies	
Simon Drysdale	PMEAG	Non-Personal	Janssen	Local PI or national CI for multiple research studies for multiple pharmaceutical companies	
Simon Drysdale	PMEAG	Additional			Member of the JCVI RSV subcommittee
Simon Drysdale	PMEAG	Non-Personal	Pfizer	Local PI or national CI for multiple research studies for multiple pharmaceutical companies	
Siow-Ming Lee	OHEAG	Personal	NIL	N/A	N/A
Siow-Ming Lee	OHEAG	Non-Personal	NIL	N/A	N/A
Siow-Ming Lee	OHEAG	Conference s/Scientific Meetings	ESMO	Conference attendance	Transport and Registration Fees
Stella O'Brien	IEAG, NPPEAG	Personal	NIL	N/A	N/A
Stella O'Brien	IEAG, NPPEAG	Non-Personal	NIL	N/A	N/A
Stella O'Brien	IEAG, NPPEAG	Additional	CRUK (Cancer Research UK)	Position: Public voice member	Standard NIHR public involvement honorarium for decision-making activities

Stella O'Brien	IEAG, NPPEAG	Additional	IASLC	Graduate of their Patient Research Advocacy program	Graduate of their Patient Research Advocacy program
Stella O'Brien	IEAG, NPPEAG	Additional	University of Bristol	Public co-applicant and member of BESS (Bristol Evidence Synthesis for Screening) Group which prepares evidence products for the NSC (National Screening Committee)	
Stella O'Brien	IEAG, NPPEAG	Additional	HIS (Healthcare Infection Society)	Public member of Surface Sampling Guidelines Working Group	Standard NIHR public involvement honorarium
Stella O'Brien	IEAG, NPPEAG	Additional	NHS England	Public member, Quality Committee	Strategic Co-Production Group for IRLSS (Innovation, Research, Life Sciences and Strategy)
Stella O'Brien	IEAG, NPPEAG	Additional	NICE	Lay member	Standard NIHR public involvement honorarium.
Stella O'Brien	IEAG, NPPEAG	Additional	NIHR	Public member	Standard NIHR public involvement honorarium
Stella O'Brien	IEAG, NPPEAG	Additional	Our Future Health	Public member of Public Advisory Board	
Stella O'Brien	IEAG, NPPEAG	Additional	THIS (The Health Improvement Studies) Institute Cambridge	Chair Engagement and Involvement Committee	Standard public involvement honorarium
Stella O'Brien	IEAG, NPPEAG	Additional	HRA (Health Research Authority)	Public member for Shared Commitment to Public Involvement in Research on behalf of NHSE Strategic Co-Production Group	Standard NIHR public involvement honorarium
Stella O'Brien	IEAG, NPPEAG	Additional			Voluntary citizen member
Steven Cunningham	CHM, PMEAG	Personal	NIL	N/A	N/A
Steven Cunningham	CHM, PMEAG	Non-Personal	Gilead	Chair Data Safety Monitoring Board. Studies terminated with no activity.	

Steven Cunningham	CHM, PMEAG	Non-Personal	ArkBiosciences	Bronchiolitis RSV antiviral trial development. No activity during this period to end of agreement.	
Steven Cunningham	CHM, PMEAG	Non-Personal	Boehringer Ingelheim	Trial steering committee with employer fees paid to the University of Edinburgh.	
Stuart H Ralston	GRIDEAG, MWHEAG	Personal	NIL	N/A	N/A
Stuart H Ralston	GRIDEAG, MWHEAG	Conference s/Scientific Meetings	UCB	Travel Expenses	
Stuart H Ralston	GRIDEAG, MWHEAG	Conference s/Scientific Meetings	UCB	Travel Expenses	
Stuart H Ralston	GRIDEAG, MWHEAG	Non-Personal	Abbvie	Educational grant	
Stuart H Ralston	GRIDEAG, MWHEAG	Non-Personal	CSL Vifor	Educational grant	
Stuart H Ralston	GRIDEAG, MWHEAG	Non-Personal	Novartis	Educational grant	
Stuart H Ralston	GRIDEAG, MWHEAG	Non-Personal	Thornton and Ross	Educational grant	
Stuart H Ralston	GRIDEAG, MWHEAG	Non-Personal	UCB	Educational grant	
Stuart H Ralston	GRIDEAG, MWHEAG	Non-Personal	UCB	Consultancy	
Stuart H Ralston	GRIDEAG, MWHEAG	Non-Personal	Angitia	Consultancy	
Stuart H Ralston	GRIDEAG, MWHEAG	Non-Personal	Angitia	Research study (not yet commenced)	
Stuart H Ralston	GRIDEAG, MWHEAG	Non-Personal	Kyowa Kirin		
Stuart H Ralston	GRIDEAG, MWHEAG	Non-Personal	Kyowa Kirin	Educational grant	
Stuart H Ralston	GRIDEAG, MWHEAG	Non-Personal	TD Cowan	Consultancy	

Stuart H Ralston	GRIDEAG, MWHEAG	Non-Personal	Fresenius-Kabi	Educational grant	
Stuart H Ralston	GRIDEAG, MWHEAG	Non-Personal	Johnston & Johnston	Educational grant	
Stuart H Ralston	GRIDEAG, MWHEAG	Non-Personal	Sanofi-Genzyme	Educational grant	
Stuart H Ralston	GRIDEAG, MWHEAG	Non-Personal	Amgen	Educational grant	
Stuart H Ralston	GRIDEAG, MWHEAG	Non-Personal	Boehringer Ingelheim	Educational grant	
Stuart H Ralston	GRIDEAG, MWHEAG	Non-Personal	Ascendis	Consultancy	
Stuart H Ralston	GRIDEAG, MWHEAG	Non-Personal	Relation Therapeutics	Consultancy	
Stuart H Ralston	GRIDEAG, MWHEAG	Additional			Chairman of the Board of Trustees of the Paget's Association. Co-chair of the Board of Trustees of PAO UK
Susan Hunneyball	PEAG, ARMEWG	Personal	NIL	N/A	N/A
Susan Hunneyball	PEAG, ARMEWG	Non-Personal	NIL	N/A	N/A
Susan Hunneyball	PEAG, ARMEWG	Additional			Write articles published in the Chemist and Druggist magazine, a trade magazine for pharmacists but receive no payment for those articles. The information referred to is in the public domain. Only personal views are reflected and all sources of information used are referenced.
Susannah Walsh	CPSEAG	Personal	Better Vision Solutions	Consultancy and licence agreement for technology. Named on patents.	

Susannah Walsh	CPSEAG	Personal	Chemical Biological Center of Combat Capabilities Development Command and Defence Threat Reduction Agency	Research collaboration and MTA. Named on DMU Patents associated with work.	
Susannah Walsh	CPSEAG	Personal	Techfest	Director	
Susannah Walsh	CPSEAG	Personal	University of Wolverhampton	External examiner	
Susannah Walsh	CPSEAG	Personal	Kingston University	External examiner	
Susannah Walsh	CPSEAG	Personal	Safer Disinfectant Network	Attended some online meetings involving academics and disinfection companies run by the Safer Disinfectant Network, prior to 2024. No personal links to the companies who are signed up to their charter (to promote best practice and support public health in the workplace) beyond those detailed above.	Not attended a meeting for more than two years
Susannah Walsh	CPSEAG	Non-Personal	NIL	N/A	N/A
Susannah Walsh	CPSEAG	Additional			Member of Pharmacy Schools Council executive and National Pharmacy Workforce Forum and associated sub-groups
Sylvia Kama-Kieghe	MWHEAG	Personal	NIL	N/A	N/A
Sylvia Kama-Kieghe	MWHEAG	Non-Personal	NIL	N/A	N/A
Sylvia Kama-Kieghe	MWHEAG	Additional			Member, Board of Trustees College of Sexual and Reproductive Healthcare

(November 2021 to date)
Vice President Membership & Workforce, College of Sexual & Reproductive Healthcare appointment commenced September 2025.
These roles involve events (e.g. conferences) or meetings that involve pharmaceutical organisations or MAHs which develop medicines or devices relating to women's health.

Teresa Lambe	CTBVEAG	Personal	Infinitopes Limited	Consultancy - SAB	
Teresa Lambe	CTBVEAG	Personal	Geovax Labs Inc	Consultancy - SAB	
Teresa Lambe	CTBVEAG	Personal	ARABIO	Consultancy	Two meetings
Teresa Lambe	CTBVEAG	Personal	aVaxzipen Limited	Consultancy	One SAB meeting
Teresa Lambe	CTBVEAG	Personal	Seqirus UK Limited	Consultancy	One, one-hour meeting in March
Teresa Lambe	CTBVEAG	Personal	AstraZeneca	Grant	Funds for storage of serum and PBMC samples from the Oxford-AZ clinical trials used for licensure of Vaxzevria/Covishield
Teresa Lambe	CTBVEAG	Conference s/Scientific Meetings	ESCMID, Vienna - Sanofi	Travel Expenses	
Teresa Lambe	CTBVEAG	Non-Personal	NIL	N/A	N/A
Teresa Lambe	CTBVEAG	Additional			Associate Head of the Dept of Paediatrics (People & Culture) and work within Oxford Vaccine Group who have received funds for fellowships, partnerships or research activities from Ellison Institute of Technology, Moderna, GSK, Pfizer Inc,

MCM Vaccine B.V., Merck, and Serum Institute of India. Not privy to the outputs or findings from these fellowships, partnerships or research activities and so cannot describe which product or group of products this may relate to.

Theresa McDonagh	CDRRA EAG	Personal	Boehringer Ingelheim	Consultancy	
Theresa McDonagh	CDRRA EAG	Non-Personal	NIL	N/A	N/A
Thomas Fairfax	PEAG	Personal	NIL	N/A	N/A
Thomas Fairfax	PEAG	Non-Personal	NIL	N/A	N/A
Tom Clutton-Brock	HPMEWG	Personal	NIL	N/A	N/A
Tom Clutton-Brock	HPMEWG	Non-Personal	NIL	N/A	N/A
Tom Clutton-Brock	HPMEWG	Additional			Director, Medical Devices Testing and Evaluation Centre Clinical Director, NIHR HealthTech Research Centre in Devices, Digital and Robotics Chair, NICE Diagnostics Advisory Committee Associate Medical Director, University Hospitals Birmingham NHS Foundation Trust Professor of Anaesthesia & Intensive Care Medicine, University of Birmingham, Chair of the interim Devices Working Group, Member of the

					National Commission on the Regulation of AI in Healthcare, Health Systems Working Group, MHRA
Vanessa Raymont	CHM, ARMEWG	Personal	NIL	N/A	N/A
Vanessa Raymont	CHM, ARMEWG	Conference s/Scientific Meetings	Eli Lilly	Travel expenses to meeting	
Vanessa Raymont	CHM, ARMEWG	Conference s/Scientific Meetings	Roche Diagnostics	None	
Vanessa Raymont	CHM, ARMEWG	Non-Personal	Janssen	In kind plasma biomarker assay support for a research study mainly funded by a Medical Research Council grant, for which the role of Chief Investigator is held.	
Vanessa Raymont	CHM, ARMEWG	Non-Personal	Eli Lilly	Staffing costs provided via a Collaborative Working Agreement to do a pilot project to expand CSF testing in NHS memory clinics for which the role of Chief Investigator is held.	
Vanessa Raymont	CHM, ARMEWG	Non-Personal	Eisai	Staffing costs provided for a Delphi Consensus on data to collect in an Alzheimer's drugs treatment register in UK	
Vanessa Raymont	CHM, ARMEWG	Additional			Acted as local site Principal Investigator for commercial clinical trials for the following companies: AC Immune J and J AriBio BMS Roche

Merck Novartis					
Vitaliy Khutoryanskiy	CPSEAG	Personal	NIL	N/A	N/A
Vitaliy Khutoryanskiy	CPSEAG	Non-Personal	MC2 THERPEUTICS	Hold a Royal Society Industry fellowship and collaborate with MC2 Therapeutics on the studies of various topical and mucosal formulations	
Wajid Hussain	CDRRA EAG	Personal	NIL	N/A	N/A
Wajid Hussain	CDRRA EAG	Non-Personal	NIL	N/A	N/A
Waqar Rashid	NPPEAG	Personal	NIL	N/A	N/A
Waqar Rashid	NPPEAG	Non-Personal	NIL	N/A	N/A
William Herrington	CDRRA EAG	Personal	NIL	N/A	N/A
William Herrington	CDRRA EAG	Non-Personal	Eli Lilly	Grant to the University of Oxford for EMPA-KIDNEY (Chief Investigator)	N/A
William Herrington	CDRRA EAG	Non-Personal	Boehringer Ingelheim	Grant to the University of Oxford for EMPA-KIDNEY and EASi-KIDNEY (Chief Investigator)	N/A
William John Watkins	PMEAG	Personal	NIL	N/A	N/A
William John Watkins	PMEAG	Non-Personal	NIL	N/A	N/A
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Personal	NIL	N/A	N/A
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	Imperial College London	Research Collaborator: VaxHub Grant to University of Strathclyde.	
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	Microfluidics Inc	Equipment loan to University of Strathclyde and in-kind research support (consumables).	

Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	Avanti polar lipids/CRODA	BBSRC Icase PhD studentship grant to University of Strathclyde
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	AstraZeneca	PhD studentships including Icase.
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	Defence Threat Reduction Agency DTRA (administered by DSTL)	Research Grant to University of Strathclyde
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	Target Healthcare	Knowledge Transfer Partnership research Grant to University of Strathclyde
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	Takeda / Millenium Pharmaceuticals	Knowledge exchange research contracts from company to University of Strathclyde
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	LEON Nano Drugs GmbH	Knowledge exchange research contracts from company to University of Strathclyde
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	Precision Nanomedicines Inc	Knowledge exchange research contracts from company to University of Strathclyde and joint PhD funding. Equipment loan to University of Strathclyde to support project.
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	NOF CORPORATION	Knowledge exchange research contracts from company to University of Strathclyde
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	Micropore Technologies Ltd	Knowledge exchange research contracts from company to University of Strathclyde and joint PhD funding. Equipment loan to University of Strathclyde. Innovate UK grant.
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	ABITEC	Joint PhD funding.

Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	Centre for process Innovation Ltd	Research Grant to University of Strathclyde.
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	Micropore ABITEC AstraZeneca Colorcon Croda	Co-I on PhD CDT Training programme CMAC CEDAR - https://www.cmac.ac.uk/cedar
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	Syncona Ltd	Knowledge Transfer Partnership research Grant to University of Strathclyde
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	N4 Pharma	Knowledge Transfer Partnership research Grant to University of Strathclyde
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	Phillips Medisize, a molex company	Knowledge Transfer Partnership research Grant to University of Strathclyde
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	Boehringer Ingelheim	Knowledge Transfer Partnership research Grant to University of Strathclyde
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	Pfizer Sanofi Chiesi UCB Takeda Lilly Roche	Whilst not directly linked to Nanomedicines theme in the PhD CDT programme, other companies are linked to the grant.
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Additional		Head of Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS), an internationally leading technological University and working with many companies across the dept, faculty and University. Also work with Health care providers including a wide range of NHS trusts and

pharmacies through both
research and education.

Contact information about these reports:

Medicines and Healthcare products Regulatory Agency
Customer Services
10 South Colonnade
Canary Wharf
London E14 4PU

Tel: 020 3080 6000

E-mail: info@mhra.gov.uk

© Crown copyright 2026

Published by the Medicine and Healthcare products Regulatory Agency

ISBN 978-1-8384147-4-0

Guidance on reproducing and re-using MHRA Crown copyright material can be found on our website at: <http://www.nationalarchives.gov.uk/information-management/re-using-public-sector-information/copyright-and-re-use/crown-copyright/>